{"id":2916,"date":"2018-07-05T06:00:55","date_gmt":"2018-07-04T21:00:55","guid":{"rendered":"https:\/\/www.muscle-hypertrophy.com\/?p=2916"},"modified":"2018-07-05T07:54:43","modified_gmt":"2018-07-04T22:54:43","slug":"%e3%83%88%e3%83%ac%e3%83%bc%e3%83%8b%e3%83%b3%e3%82%b0%e3%81%ae%e6%9c%80%e9%81%a9%e5%8c%96%ef%bc%9a%e5%ae%89%e5%85%a8%e3%81%aa%e7%ad%8b%e5%8a%9b%e3%83%88%e3%83%ac%e3%83%bc%e3%83%8b%e3%83%b3%e3%82%b0","status":"publish","type":"post","link":"https:\/\/www.muscle-hypertrophy.com\/?p=2916","title":{"rendered":"\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e\u6700\u9069\u5316\uff1a\u5b89\u5168\u306a\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306b\u304a\u3051\u308b\u65b0\u3057\u3044\u9032\u5c55"},"content":{"rendered":"

\u3000\u4f4e\u5f37\u5ea6\u3068\u9ad8\u5f37\u5ea6\u3068\u306e\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306b\u304a\u3051\u308b\u7b4b\u529b\u3068\u7b4b\u80a5\u5927\u306e\u9069\u5fdc\uff0c\u30b7\u30b9\u30c6\u30de\u30c6\u30a3\u30c3\u30af\u30ec\u30d3\u30e5\u30fc\u3068\u30e1\u30bf\u30a2\u30ca\u30ea\u30b7\u30b9<\/a>\u306b\u304a\u3044\u3066\u53c2\u8003\u6587\u732e\u306e\u4e00\u3064\u306b\u6319\u3052\u3089\u308c\u3066\u3044\u305f\u8ad6\u6587\u3092\u6284\u8a33\u3059\u308b\uff0e\u30ed\u30b7\u30a2\u304b\u3089\u306e\u7b4b\u751f\u691c\u3092\u542b\u3080\u8cb4\u91cd\u306a\u5831\u544a\u3067\u3042\u308b\uff0e\u3053\u306e\u3088\u3046\u306a\u4fb5\u8972\u7684\u306a\u691c\u67fb\u306f\u65e7\u5171\u7523\u570f\u3060\u304b\u3089\u53ef\u80fd\u306a\u306e\u304b\u3082\u77e5\u308c\u306a\u3044\uff0e<\/p>\n

\u3000\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u8ca0\u8377\u306e\u8efd\u91cd\u306e\u9055\u3044\u3067\u80a5\u5927\u3059\u308b\u7b4b\u7e4a\u7dad\u306e\u578b\u304c\u7570\u306a\u308b\uff0c\u3068\u3044\u3046\u5f15\u7528\u3060\u3051\u3092\u629c\u7c8b\u3059\u308b\u3064\u3082\u308a\u3060\u3063\u305f\u306e\u304c\uff0c\u7b4b\u5f62\u6210\u8abf\u7bc0\u907a\u4f1d\u5b50\u306b\u307e\u3067\u8a00\u53ca\u3057\u3066\u304a\u308a\uff0c\u307b\u307c\u5168\u8a33\u3068\u306a\u3063\u3066\u3057\u307e\u3063\u305f\uff0e\u4e8c\u9031\u9593\u3082\u304b\u304b\u3063\u3066\u3057\u307e\u3046\u306e\u3067\u306f\u52b9\u7387\u304c\u60aa\u3059\u304e\u308b\u306e\u3060\u304c\uff0c\u3053\u3053\u306f\u52c9\u5f37\u3068\u601d\u3063\u3066\u6211\u6162\u3057\u3088\u3046\uff0e<\/p>\n

<\/p>\n

Optimization of Training: New Developments in Safe Strength Training (Human Physiology, 2013, Vol. 39, No. 5, pp. 511\u2013523)<\/a><\/h3>\n

Abstract<\/h3>\n

The hypertrophic effect of strength training is known to be due to mechanical and metabolic stimuli. During exercises with the restricted blood supply of working muscles, i.e., under the conditions of intensified metabolic stress, the training effect may be achieved with much lower external loads (20% of one repetition maximum). The effects of 8 weeks of high intensity (80\u201385% of one repetition maximum) strength training were compared to low intensity (50% of one repetition maximum) training without relaxation. The high intensity strength training resulted in higher increases in strength and size of the exercised muscles than training without relaxation. During high intensity training, at the muscle cross section, an increase in the area occupied by type II fibers prevails; while, during training without relaxation, an increase in the area occupied by type I fibers prevails. An exercise session without relaxation leads to a more pronounced increase in the secretion of the growth hormone, insulin like growth factor 1, and cortisol. The expression of gene regulating myogenesis (Myostatin) is changed in different ways after a high intensity strength exercise session and after an exercise session without relaxation. Low intensity strength training (50% of one repetition maximum) without relaxation is an efficient way for inducing increases of the strength and size of the trained muscles. This low intensive type of training may be used in rehabilitation medicine, sports, and fitness.<\/p>\n

\u3000\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e\u80a5\u5927\u52b9\u679c\u306f\u6a5f\u68b0\u7684\u523a\u6fc0\u304a\u3088\u3073\u4ee3\u8b1d\u7684\u523a\u6fc0\u306b\u3088\u308b\u3053\u3068\u304c\u77e5\u3089\u308c\u3066\u3044\u308b\uff0e\u8840\u6db2\u306e\u4f9b\u7d66\u3092\u5236\u9650\u3057\u305f\u904b\u52d5\u4e2d\uff0c\u4f8b\u3048\u3070\u4ee3\u8b1d\u30b9\u30c8\u30ec\u30b9\u306e\u5f37\u5316\u3055\u308c\u305f\u6761\u4ef6\u4e0b\u306a\u3069\u3067\u306f\uff0c\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u52b9\u679c\u306f\u3088\u308a\u6975\u7aef\u306b\u4f4e\u3044\u5916\u90e8\u8ca0\u8377 (20% 1RM) \u306b\u304a\u3044\u3066\u9054\u6210\u3055\u308c\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\uff0e8 \u9031\u9593\u306e\u9ad8\u5f37\u5ea6\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0 (80-85% 1RM) \u306e\u52b9\u679c\u3068\u5f1b\u7de9\u306a\u3057\u306e\u4f4e\u5f37\u5ea6\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0 (50% 1RM) \u306e\u52b9\u679c\u3068\u3092\u6bd4\u8f03\u3057\u305f\uff0e\u9ad8\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306f\u5f1b\u7de9\u306a\u3057\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3088\u308a\u3082\u7b4b\u529b\u304a\u3088\u3073\u904b\u52d5\u3057\u305f\u7b4b\u8089\u306e\u5927\u304d\u3055\u306b\u304a\u3044\u3066\u3088\u308a\u9ad8\u3044\u5897\u52a0\u3092\u3082\u305f\u3089\u3057\u305f\uff0e\u9ad8\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e\u9593\uff0c\u7b4b\u65ad\u9762\u7a4d\u306b\u304a\u3044\u3066\u306f II \u578b\u7dda\u7dad\u306e\u9762\u7a4d\u304c\u512a\u5148\u7684\u306b\u5897\u52a0\u3057\u305f\uff0e\u4e00\u65b9\u3067\uff0c\u5f1b\u7de9\u306a\u3057\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e\u9593\u306f I \u578b\u7dda\u7dad\u306e\u9762\u7a4d\u304c\u512a\u5148\u7684\u306b\u5897\u52a0\u3057\u305f\uff0e\u5f1b\u7de9\u306a\u3057\u306e\u904b\u52d5\u30bb\u30c3\u30b7\u30e7\u30f3\u3067\u306f\u6210\u9577\u30db\u30eb\u30e2\u30f3\uff0cIGF-1 \u304a\u3088\u3073\u30b3\u30eb\u30c1\u30be\u30fc\u30eb\u306e\u5206\u6ccc\u304c\u3088\u308a\u9855\u8457\u306b\u5897\u52a0\u3059\u308b\uff0e\u7b4b\u5f62\u6210\u8abf\u7bc0\u907a\u4f1d\u5b50\uff08\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\uff09\u306f\uff0c\u9ad8\u5f37\u5ea6\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e\u5f8c\u3068\u5f1b\u7de9\u306a\u3057\u306e\u4f4e\u5f37\u5ea6\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e\u5f8c\u3068\u3067\u306f\uff0c\u7570\u306a\u308b\u7d4c\u8def\u3067\u767a\u73fe\u3059\u308b\uff0e\u5f1b\u7de9\u306a\u3057\u306e\u4f4e\u5f37\u5ea6\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0 (50% 1RM) \u306f\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3057\u305f\u7b4b\u8089\u306e\u7b4b\u529b\u3068\u5927\u304d\u3055\u3092\u5897\u52a0\u3055\u305b\u308b\u52b9\u679c\u7684\u306a\u65b9\u6cd5\u3067\u3042\u308b\uff0e\u3053\u306e\u4f4e\u5f37\u5ea6\u578b\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306f\u30ea\u30cf\u30d3\u30ea\u30c6\u30fc\u30b7\u30e7\u30f3\u533b\u5b66\uff0c\u30b9\u30dd\u30fc\u30c4\u304a\u3088\u3073\u30d5\u30a3\u30c3\u30c8\u30cd\u30b9\u306b\u6d3b\u7528\u3057\u3046\u308b\uff0e<\/p>\n

Keywords<\/h3>\n

strength training, skeletal muscle, muscle fibers, anabolic hormones, gene expression<\/p>\n

MATERIALS AND METHODS<\/h3>\n

\u30008-10 \u9031\u9593\u306e\u671f\u9593\u3067\u9ad8\u5f37\u5ea6\u7fa4\u3068\u3057\u3066 80-85% 1RM \u304a\u3088\u3073\uff0c\u4f4e\u5f37\u5ea6\u7fa4\u3068\u3057\u3066 50-70% 1RM \u5f1b\u7de9\u306a\u3057\u3068\u3057\uff0c\u7a2e\u76ee\u306f\u30ec\u30c3\u30b0\u30a8\u30af\u30b9\u30c6\u30f3\u30b7\u30e7\u30f3\uff08L \u30b7\u30ea\u30fc\u30ba\uff09\u3068\u30cb\u30fc\u30a8\u30af\u30b9\u30c6\u30f3\u30b7\u30e7\u30f3\uff08K \u30b7\u30ea\u30fc\u30ba\uff09\uff0c\u7b4b\u8089\u306e\u5f62\u614b\u5b66\u7684\u5909\u5316\u3092\u8a08\u6e2c\u3059\u308b\u306e\u306b MRI \u3092\u7528\u3044\uff0c\u751f\u5316\u5b66\u7684\u691c\u67fb\u304a\u3088\u3073\u5185\u5206\u6ccc\u5b66\u7684\u691c\u67fb\uff0c\u3055\u3089\u306b\u7b4b\u751f\u691c\u3092\u65bd\u884c\u3057\u305f\uff0e<\/p>\n

\u3000I \u578b\u304a\u3088\u3073 II \u578b\u7b4b\u7dda\u7dad (MFI, MFII) \u306b\u3088\u308a\u5360\u3081\u3089\u308c\u308b\u9762\u7a4d\u306f\u5916\u5074\u5e83\u7b4b\u306e\u65ad\u9762\uff0c\u3064\u307e\u308a\u7b4b\u8089\u5185\u306e\u3053\u306e\u578b\u306e\u7dda\u7dad\u306e\u7d44\u6210\u306e\u5272\u5408\u306b\u3053\u306e\u578b\u306e\u7b4b\u7dda\u7dad\u65ad\u9762\u7a4d\u3092\u304b\u3051\u3066\u6c42\u3081\u305f\uff0e<\/p>\n

\u3000\u63a1\u8840\u691c\u67fb\u306f\u521d\u671f\uff08\u7b2c 2 \u9031\uff09\u304a\u3088\u3073\u5f8c\u671f\uff08\u7b2c 7 \u9031\uff09\u306b\u65bd\u884c\u3057\u305f\uff0e\u6bd4\u8f03\u306e\u305f\u3081\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u306e\u4f11\u606f\u6642\u3068\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e 1 \u30bb\u30c3\u30b7\u30e7\u30f3\u5f8c\u306b\u63a1\u8840\u3057\u305f\uff0e\u9805\u76ee\u306f\u4e73\u9178\uff0c\u6210\u9577\u30db\u30eb\u30e2\u30f3 (GH), \u30a4\u30f3\u30b9\u30ea\u30f3\u69d8\u6210\u9577\u56e0\u5b50 (IGF-1), \u30c6\u30b9\u30c8\u30b9\u30c6\u30ed\u30f3\u304a\u3088\u3073\u30b3\u30eb\u30c1\u30be\u30fc\u30eb\u3067\u3042\u308b\uff0e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u30bb\u30c3\u30b7\u30e7\u30f3\u524d\u3068 18 \u6642\u9593\u5f8c\u306b\u8840\u6e05\u30af\u30ec\u30a2\u30c1\u30f3\u30ad\u30ca\u30fc\u30bc\u6d3b\u6027 (CK), \u5fc3\u7b4b\u30a2\u30a4\u30bd\u30d5\u30a9\u30fc\u30e0 (CK-MB) \u3092\u6e2c\u5b9a\u3057\u305f\uff0e\u6a2a\u7d0b\u7b4b\u7531\u6765\u306e CK (CK-MM) \u306f\u8a08\u7b97\u3067\u6c42\u3081\u305f\uff0e<\/p>\n

\u3000\u7b4b\u5f62\u6210\u8abf\u7bc0\u907a\u4f1d\u5b50\u306e\u767a\u73fe\u306e\u5909\u5316\u306f 1 \u30bb\u30c3\u30b7\u30e7\u30f3\u524d, 5 \u6642\u9593\u5f8c, 22 \u6642\u9593\u5f8c\u306b\u884c\u3044\uff0c\u30ea\u30a2\u30eb\u30bf\u30a4\u30e0 PCR \u6cd5\u3092\u7528\u3044\u305f\uff0e<\/p>\n

\u3000\u30ef\u30fc\u30af\u30a2\u30a6\u30c8\u5f53\u65e5\u306f\u88ab\u9a13\u8005\u306f\u901a\u5e38\u306e\u671d\u98df\u3092\u6442\u3063\u3066 1 \u6642\u9593\u5f8c\u306b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u30bb\u30c3\u30b7\u30e7\u30f3\u3092\u884c\u3044\uff0c\u901a\u5e38\u306e\u663c\u98df\u3092\u6442\u3063\u305f\uff0e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u524d\u3068 15 \u5206\u5f8c\u306b\u9759\u8108\u8840\u3092\u63a1\u8840\u3057\u3066\u30db\u30eb\u30e2\u30f3\u5024\u3092\u6e2c\u5b9a\u3057\u305f\uff0e3 \u30bb\u30c3\u30c8\u5f8c\uff0c5 \u30bb\u30c3\u30c8\u5f8c\uff0c8 \u30bb\u30c3\u30c8\u5f8c\u306b\u6307\u306e\u6bdb\u7d30\u8840\u7ba1\u304b\u3089\u63a1\u8840\u3057\u3066\u4e73\u9178\u5024\u3068\u30b0\u30eb\u30b3\u30fc\u30b9\u6fc3\u5ea6\u3092\u6e2c\u5b9a\u3057\u305f\uff0e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u524d\uff0c5 \u6642\u9593\u5f8c\uff0c22 \u6642\u9593\u5f8c\u306b micro-biopsy technique \u3092\u7528\u3044\u3066\u5916\u5074\u5e83\u7b4b\u306e\u7b4b\u7d44\u7e54\u6a19\u672c\u3092\u63a1\u53d6\u3057\u305f\uff0e<\/p>\n

\u3000\u7b4b\u8089\u306e\u5f62\u614b\u8a08\u6e2c\u30d1\u30e9\u30e1\u30fc\u30bf\u3092\u63a8\u5b9a\u3059\u308b\u306e\u306b\u5927\u817f\u56db\u982d\u7b4b\u3068\u5927\u6bbf\u7b4b\u3092 MRI \u3067\u8a08\u6e2c\u3057\u305f\uff0e<\/p>\n

\u3000I \u578b\u304a\u3088\u3073 II \u578b\u7b4b\u7dda\u7dad\u306e\u65ad\u9762\u7a4d\u3092\u5916\u5074\u5e83\u7b4b\u306e needle biopsy technique (29<\/a>) \u306b\u3088\u308a\u7b4b\u751f\u691c\u6a19\u672c\u6a2a\u65ad\u9762\u3092\u8a55\u4fa1\u3057\u305f\uff0e\u5206\u6790\u524d\u306b -20 °C \u3067\u30de\u30a4\u30af\u30ed\u30c8\u30fc\u30e0\u3092\u7528\u3044\u3066\u539a\u3055 5 µm \u306b\u51cd\u7d50\u5207\u7247\u306b\u8584\u5207\u3057\uff0c\u7b4b\u7dda\u7dad\u306b\u6cbf\u3063\u3066\u9023\u7d9a\u5207\u7247\u3092\u5782\u76f4\u306b\u7a4d\u307f\u4e0a\u3052\u305f\uff0eI \u578b\u304a\u3088\u3073 II \u578b\u7b4b\u7dda\u7dad\u306f NCL-MHCf (a+b) \u304a\u3088\u3073 NCL-MHCs \u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53 (Novocastra laboratories) \u3092\u7528\u3044\u305f\u514d\u75ab\u7d44\u7e54\u5316\u5b66\u67d3\u8272\u306b\u3088\u308a\u691c\u51fa\u3057\u305f\uff0e\u305d\u3057\u3066\uff0cFITS \u3067\u6a19\u8b58\u3057\u305f\u4e8c\u6b21\u6297\u4f53\u3092\u7528\u3044\u305f\uff0e\u8a08\u6e2c\u306f\u30ab\u30fc\u30eb\u30c4\u30a1\u30a4\u30b9\u88fd Axiovert-200 \u9855\u5fae\u93e1\u3067\u884c\u3063\u305f\uff0e\u5404\u3005\u306e\u7d44\u7e54\u6a19\u672c\u306b\u3064\u304d\uff0c\u305d\u308c\u305e\u308c\u306e\u578b\u306b\u3064\u304d\u6700\u4f4e 100 \u306e\u7b4b\u7dda\u7dad\u3092\u8a08\u6e2c\u3057\u305f\uff0e<\/p>\n

\u3000\u7b4b\u7d44\u7e54\u304b\u3089\u306e RNA \u5358\u96e2\u306f\u7c73\u56fd Invitrogen \u88fd\u306e TRIZOL \u30bb\u30c3\u30c8\u306b\u3066\u884c\u3063\u305f\uff0e\u76f8\u88dc\u7684 DNA \u306f\u30ed\u30b7\u30a2\u88fd Sileks \u30bb\u30c3\u30c8\u306b\u3066\u5f97\u305f\uff0e<\/p>\n

\u3000\u30dd\u30ea\u30e1\u30e9\u30fc\u30bc\u9023\u9396\u53cd\u5fdc\uff0e\u30ea\u30a2\u30eb\u30bf\u30a4\u30e0 PCR \u6cd5\u306f\u30ed\u30b7\u30a2 Synthol \u88fd\u306e SybrGreen \u30bb\u30c3\u30c8\u306b\u3066\u884c\u3063\u305f\uff0e\u6a19\u672c\u4e2d\u306e\u30a4\u30f3\u30b9\u30ea\u30f3\u69d8\u6210\u9577\u56e0\u5b50 (IGF-1Ea) \u304a\u3088\u3073\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\u306e\u907a\u4f1d\u5b50\u767a\u73fe\u91cf\u3092\u691c\u51fa\u3057\u305f\uff0e\u53c2\u7167\u907a\u4f1d\u5b50\u3068\u3057\u3066\u30ea\u30dc\u30be\u30fc\u30e0\u30bf\u30f3\u30d1\u30af P0<\/sub> \u304a\u3088\u3073 β \u30a2\u30af\u30c1\u30f3\u3092\u7528\u3044\u305f\uff0e\u6a19\u7684\u907a\u4f1d\u5b50\u306e\u767a\u73fe\u91cf\u5909\u5316\u306f\u6587\u732e 30<\/a> \u306b\u5f93\u3063\u3066\u691c\u51fa\u3057\uff0c\u6a19\u7684\u907a\u4f1d\u5b50\u3068\u53c2\u7167\u907a\u4f1d\u5b50\u306e\u53cd\u5fdc\u52b9\u7387\u306f\u6a19\u6e96\u66f2\u7dda\u306b\u3088\u308a\u8a08\u7b97\u3057\u305f\uff0e<\/p>\n

RESULTS AND DISCUSSION<\/h3>\n

Strength training of the leg extensors (L series)<\/h4>\n

\u3000\u4e21\u8005\u306e\u578b\u306e\u7b4b\u7dda\u7dad\u306f\u9ad8\u5f37\u5ea6\u306e\u7b4b\u53ce\u7e2e\u306b\u95a2\u4e0e\u3057\u3066\u3044\u308b (32<\/a>). \u540c\u6642\u306b\u6b21\u306e\u70b9\u3082\u3088\u304f\u77e5\u3089\u308c\u3066\u3044\u308b\uff0e\u3064\u307e\u308a\uff0c\u4f1d\u7d71\u7684\u306a\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306f I \u578b\u7b4b\u7dda\u7dad\u3088\u308a\u3082 II \u578b\u7b4b\u7dda\u7dad\u306b\u304a\u3044\u3066\u6fc0\u3057\u3044\u80a5\u5927\u3092\u3082\u305f\u3089\u3059 (33,34<\/a>,35<\/a>,36<\/a>). \u304a\u305d\u3089\u304f\uff0c\u305d\u306e\u7406\u7531\u306f\u9ad8\u5f37\u5ea6\u306e\u7b4b\u8089\u306e\u4ed5\u4e8b\u304c II \u578b\u7b4b\u7dda\u7dad\u306b\u304a\u3044\u3066 I \u578b\u7b4b\u7dda\u7dad\u3088\u308a\u3082\u660e\u767d\u306a\u4ee3\u8b1d\u6027\u5909\u5316\u3092\u3082\u305f\u3089\u3059\u305f\u3081\u3067\u3042\u308d\u3046\uff0e\u3053\u308c\u306b\u3088\u308a mTORC1 \u304a\u3088\u3073 ERK1\/2 \u30b7\u30b0\u30ca\u30eb\u7d4c\u8def\u306e\u3088\u308a\u5927\u304d\u306a\u6d3b\u6027\u5316\u304c\u3082\u305f\u3089\u3055\u308c\uff0c\u30bf\u30f3\u30d1\u30af\u5408\u6210\u3092\u8abf\u6574\u3059\u308b (37<\/a>,38<\/a>). \u6211\u3005\u306e\u8a66\u9a13 (39<\/a>) \u306b\u304a\u3044\u3066\u306f LC \u7fa4\uff08\u30ec\u30c3\u30b0\u30a8\u30af\u30b9\u30c6\u30f3\u30b7\u30e7\u30f3\u9ad8\u5f37\u5ea6\u7fa4<\/strong>\uff09\u306b\u304a\u3044\u3066\uff0c\u4f5c\u52d5\u7b4b\u3067\u3042\u308b\u5916\u5074\u5e83\u7b4b\u306b\u304a\u3051\u308b II \u578b\u7b4b\u7dda\u7dad\u306e\u5360\u3081\u308b\u9762\u7a4d\u306e\u5897\u52a0\u306f 23 % \u3067\u3042\u3063\u305f\uff0e\u4e00\u65b9\u3067 I \u578b\u7b4b\u7dda\u7dad\u306b\u3064\u3044\u3066\u306f\u5909\u5316\u306f\u306a\u304f<\/strong>\uff0c\u305d\u306e\u3053\u3068\u306f\u6587\u732e\u306e\u30c7\u30fc\u30bf\u3068\u3082\u4e00\u81f4\u3059\u308b\uff0e\u3057\u304b\u3057\uff0c\u5f1b\u7de9\u306a\u3057\u306e\u4f4e\u5f37\u5ea6\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e\u5f8c\u306b<\/strong>\uff0c\u5b9a\u6027\u7684\u306a\u5dee\u7570\u306e\u5909\u5316\u304c\u4ee5\u4e0b\u306e\u30d1\u30e9\u30e1\u30fc\u30bf\u306b\u304a\u3044\u3066\u8a8d\u3081\u3089\u308c\u305f\uff0e\u3059\u306a\u308f\u3061\uff0cII \u578b\u7b4b\u7dda\u7dad\u306e\u5360\u3081\u308b\u9762\u7a4d\u306b\u306f\u5909\u5316\u304c\u306a\u304b\u3063\u305f\u4e00\u65b9\u3067\uff0cI \u578b\u7b4b\u7dda\u7dad\u306e\u5360\u3081\u308b\u9762\u7a4d\u304c 18 % \u5897\u52a0\u3057\u3066\u3044\u305f<\/strong> (Table 1<\/strong>). \u6211\u3005\u306f\u6b21\u306e\u3088\u3046\u306b\u4eee\u5b9a\u3057\u305f\uff0e\u3064\u307e\u308a\uff0c\u7b4b\u7dda\u7dad\u306b\u304a\u3044\u3066\u30de\u30fc\u30af\u3057\u305f\u4ee3\u8b1d\u30b9\u30c8\u30ec\u30b9\u304c\uff0c\u7b4b\u80a5\u5927\u306e\u30d7\u30ed\u30bb\u30b9\u3092\u958b\u59cb\u3055\u305b\u308b\u56e0\u5b50\u306e\u4e00\u3064\u306b\u306a\u308a\u3046\u308b\u306e\u3067\u306f\u306a\u3044\u304b\u3068\uff0eI \u578b\u7b4b\u7dda\u7dad\u306b\u304a\u3044\u3066\u30de\u30fc\u30af\u3057\u305f\u4ee3\u8b1d\u30b7\u30d5\u30c8\u3092\u9054\u6210\u3059\u308b\u306e\u306f\u96e3\u3057\u3044 (40<\/a>). \u3068\u3044\u3046\u306e\u3082\uff0c\u3053\u306e\u578b\u306e\u7b4b\u7dda\u7dad\u306f\u9ad8\u3044\u9178\u5316\u96fb\u4f4d\u3092\u6709\u3057\u3066\u3044\u308b\u304b\u3089\u3067\u3042\u308b\uff0e\u3057\u304b\u3057\u4ee5\u4e0b\u306e\u3053\u3068\u304c\u660e\u3089\u304b\u306b\u306a\u3063\u305f\uff0e\u3064\u307e\u308a\uff0c\u7b49\u5c3a\u6027\u53ce\u7e2e\uff08\u7b4b\u7dca\u5f35\u306b\u3088\u308b\u8840\u6d41\u963b\u5bb3\u6761\u4ef6\u4e0b\uff09\u306b\u304a\u3044\u3066\uff0c25%, 50%, 75% 1RM \u306e\u5f37\u5ea6\u3067\u5916\u5074\u5e83\u7b4b\u304c\u75b2\u52b4\u56f0\u618a\u3057\u305f\u6642\u306e\u6700\u5927\u4e73\u9178\u6fc3\u5ea6\u3092\u8a18\u9332\u3059\u308b\u3068\uff0c50% 1 RM \u306e\u6642\u306b I \u578b\u7b4b\u7dda\u7dad\u306b\u304a\u3051\u308b\u4e73\u9178\u6fc3\u5ea6\u304c\u6700\u5927\u3068\u306a\u3063\u305f (41,42<\/a>). \u660e\u3089\u304b\u306b\u3053\u308c\u306f\u4ee5\u4e0b\u306e\u4e8b\u5b9f\u306b\u3088\u308b\u3082\u306e\u3067\u3042\u308b\uff0e\u3064\u307e\u308a\uff0cdimension \u306e\u539f\u7406<\/strong>\u306b\u3088\u308b\u3068\uff0c\u3053\u306e\u7279\u5fb4\u306e\u4ed5\u4e8b\u306f\u4e3b\u306b I \u578b\u7b4b\u7dda\u7dad\u304c\u5f93\u4e8b\u3057\u3066\u3044\u308b\u306b\u9055\u3044\u306a\u304f (32<\/a>), \u305d\u308c\u306f\u3064\u307e\u308a\uff0c\u8840\u6d41\u5236\u9650\u306b\u3088\u308b\u3082\u306e\u3067\u3042\u308a\uff0c\u89e3\u7cd6\u7cfb\u306e\u6d3b\u6027\u5316\u304c\u8d77\u304d\u3066\u3044\u308b\u3053\u3068\u306b\u3088\u308b\uff0e\u3053\u306e\u3053\u3068\u306f\u6b21\u306e\u60f3\u5b9a\u306e\u571f\u53f0\u3068\u306a\u308b\uff0e\u3064\u307e\u308a\uff0c\u5f1b\u7de9\u306a\u3057\u306e 50% 1RM \u306e\u4f4e\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3067\u306f\uff0c\u7b49\u5c3a\u6027\u904b\u52d5\u3068\u540c\u69d8\u306b\uff0cI \u578b\u7b4b\u7dda\u7dad\u304c\u5b9f\u884c\u306b\u95a2\u4e0e\u3057\u3066\u304a\u308a\uff0c\u75b2\u52b4\u56f0\u618a\u306b\u81f3\u308b\u6642\u306b\u30de\u30fc\u30af\u3057\u305f\u4ee3\u8b1d\u30b7\u30d5\u30c8\u304c\u89b3\u6e2c\u3055\u308c\u308b\uff0e\u7279\u7b46\u3059\u3079\u304d\u3053\u3068\u3060\u304c\uff0cLE \u7fa4\u306b\u304a\u3044\u3066\u306f\u5404\u30bb\u30c3\u30c8\u306e\u7d42\u4e86\u306f\u88ab\u9a13\u8005\u306e\u4f5c\u52d5\u7b4b\u306e\u3072\u3069\u3044\u75b2\u52b4\u306b\u4ed8\u968f\u3057\u305f\u3082\u306e\u3067\u3042\u3063\u305f\uff0e\u3068\u540c\u6642\u306b\uff0c\u89e3\u7cd6\u7cfb\u6d3b\u6027\u5316\u306e\u30de\u30fc\u30ab\u30fc\u3067\u3042\u308b\u8840\u4e2d\u4e73\u9178\u6fc3\u5ea6\u306f LE \u7fa4\u306e\u30bb\u30c3\u30b7\u30e7\u30f3\u3067\u306f LC \u7fa4\u3088\u308a\u3082\u9ad8\u3044\u5024\u3092\u793a\u3057\u305f\uff0e<\/p>\n

\"\"<\/a>
Table 1. The comparison of the effects the traditional high-intensive strength training (control groups, C) and training without muscle relaxation (experimental groups, E) during leg extension series (L series), knee extension series (K series), and leg extension series, when the group trained with middle intensity (M series)<\/figcaption><\/figure>\n

Strength training of the knee extensors (K series)<\/h4>\n

\u300080-85% 1RM \uff08\u5bfe\u7167\u7fa4, KC \u7fa4\uff09\u306e\u5f37\u5ea6\u306b\u3088\u308b\u4f1d\u7d71\u7684\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e\u52b9\u679c\u3092\u5f1b\u7de9\u306a\u3057\u306e 50% 1RM \u4f4e\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u7fa4\uff08\u4ecb\u5165\u7fa4, KE \u7fa4\uff09\u3068\u6bd4\u8f03\u3057\u305f\uff0e10 \u9031\u9593\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u30b5\u30a4\u30af\u30eb\u671f\u9593\u306b\u304a\u3051\u308b KC \u7fa4\u3068 KE \u7fa4\u306e\u7dcf\u4ed5\u4e8b\u91cf\u306e\u9055\u3044\u306f 2 \u500d\u4ee5\u4e0a\u306b\u306a\u3063\u305f (Table 1<\/strong>). \u540c\u6642\u306b\uff0c\u819d\u4f38\u5c55\u7b4b\u306e 1RM \u306e\u5897\u52a0\u306b\u9055\u3044\u306f\u898b\u3089\u308c\u305a, KC \u7fa4\u3068 KE \u7fa4\u3067\u305d\u308c\u305e\u308c 29%, 24% \u3067\u3042\u3063\u305f (Table 1<\/strong>). <\/p>\n

\u3000\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u671f\u9593\u306b\u304a\u3051\u308b 1RM \u5897\u52a0\u306e\u89e3\u6790\u3067\u306f L \u30b7\u30ea\u30fc\u30ba\u3068 K \u30b7\u30ea\u30fc\u30ba\u3067\u6709\u610f\u5dee\u304c\u8a8d\u3081\u3089\u308c\u305f\uff0eK \u30b7\u30ea\u30fc\u30ba\u3067\u306f\u4f1d\u7d71\u7684\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u5f8c\u306e 1RM \u306e\u5897\u52a0\u306f\u5f1b\u7de9\u306a\u3057\u306e\u4f4e\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3088\u308a\u3082\u8457\u660e\u306b\u5927\u304d\u304b\u3063\u305f (35% vs. 21%). \u4e00\u65b9\u3067 K \u30b7\u30ea\u30fc\u30ba\u306b\u304a\u3044\u3066\u306f\u8a18\u9332\u3055\u308c\u305f\u7fa4\u9593\u306b\u5dee\u7570\u306f\u8a8d\u3081\u3089\u308c\u306a\u304b\u3063\u305f (29% vs. 24%). \u660e\u3089\u304b\u306b\uff0c\u3053\u308c\u3089\u306e\u9055\u3044\u306f\u4e0a\u8ff0\u3057\u305f\u4e0b\u80a2\u3068\u819d\u306e\u7b4b\u8089\u306e\u751f\u4f53\u529b\u5b66\u7684\u7279\u5fb4\uff0c\u3059\u306a\u308f\u3061\uff0c\u7b4b\u8089\u9593\u306e\u8ca0\u8377\u306e\u518d\u5206\u914d\u306b\u95a2\u9023\u3057\u3066\u3044\u308b\uff0e<\/p>\n

\u300010 \u9031\u9593\u306b\u308f\u305f\u308b\u819d\u4f38\u5c55\u7b4b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3067\uff0c\u5916\u5074\u5e83\u7b4b\u65ad\u9762\u7a4d\u306b\u5360\u3081\u308b\u7570\u306a\u308b\u578b\u306e\u7b4b\u7dda\u7dad\u306e\u9762\u7a4d\u3092\u8a55\u4fa1\u3059\u308b\u3068, KC \u7fa4\u3067\u306e II \u578b\u7b4b\u7dda\u7dad\u3068 KE \u7fa4\u306e I \u578b\u7b4b\u7dda\u7dad\u3068\u306f\u4f3c\u305f\u3088\u3046\u306a\u5897\u52a0\u3092\u793a\u3057\u3066\u3044\u308b\u306e\u304c\u5206\u304b\u308b (Table 1<\/strong>). \u3053\u308c\u306f L \u30b7\u30ea\u30fc\u30ba\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3067\u3082\u89b3\u6e2c\u3055\u308c\u305f\u7d50\u679c\u306b\u3088\u304f\u5408\u81f4\u3059\u308b\uff0e<\/p>\n

\u3000\u3086\u3048\u306b\uff0c\u819d\u3068\u4e0b\u80a2\u4f38\u5c55\u7b4b\u306e\u9577\u671f\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e\u52b9\u679c\u306e\u6bd4\u8f03\u3092\u3082\u3068\u306b\uff0c\u6211\u3005\u306f\u6b21\u306e\u3088\u3046\u306b\u7d50\u8ad6\u4ed8\u3051\u305f\uff0e(1) \u30ec\u30c3\u30b0\u30a8\u30af\u30b9\u30c6\u30f3\u30b7\u30e7\u30f3\u306b\u304a\u3051\u308b\u819d\u4f38\u5c55\u7b4b\u3068\u81c0\u90e8\u4f38\u5c55\u7b4b\u306e\u80a5\u5927\u306e\u7a0b\u5ea6\u306f\u904b\u52d5\u306e\u751f\u4f53\u529b\u5b66\u306b\u4f9d\u5b58\u3059\u308b. (2) \u7b4b\u8089\u9593\u306e\u8ca0\u8377\u306e\u518d\u5206\u914d\u306e\u7d50\u679c\u3068\u3057\u3066\uff0c\u5f1b\u7de9\u306a\u3057\u306e\u4f4e\u5f37\u5ea6\u3067\u306e\u30ec\u30c3\u30b0\u30a8\u30af\u30b9\u30c6\u30f3\u30b7\u30e7\u30f3\u306b\u304a\u3051\u308b\u7b4b\u529b\u5897\u52a0\u306f\u4f1d\u7d71\u7684\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3088\u308a\u3082\u52a3\u308b. (3) \u819d\u4f38\u5c55\u7b4b\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e\u4f8b\u3068\u3057\u3066\uff0c\u5f1b\u7de9\u306a\u3057\u4f4e\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u304c\u4f1d\u7d71\u7684\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3068\u540c\u7b49\u306e\u819d\u4f38\u5c55\u7b4b\u306e\u7b4b\u529b\u5897\u52a0\u306b\u81f3\u3063\u305f\u4f8b\u3082\u3042\u308b. (4) \u819d\u4f38\u5c55\u7b4b\u306e\u5f1b\u7de9\u306a\u3057\u4f4e\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306f\uff0c\u30ec\u30c3\u30b0\u30a8\u30af\u30b9\u30c6\u30f3\u30b7\u30e7\u30f3\u540c\u69d8\uff0c\u7b4b\u529b\u5897\u52a0\u3092\u3082\u305f\u3089\u3057\uff0c\u305d\u308c\u306f\u4e3b\u306b I \u578b\u7b4b\u7dda\u7dad\u306e\u80a5\u5927\u306b\u3088\u308b\uff0e<\/p>\n

Strength training of medium-intensity without relaxation (M series)<\/h4>\n

\uff08\u7565\uff09<\/p>\n

An increase in the muscle mass and strength during low-intensity training without relaxation is related to hormonal adaptation<\/h4>\n

\u3000\u4e0a\u8ff0\u3057\u305f\u3088\u3046\u306b\uff0c\u7b4b\u80a5\u5927\u306f\u6a5f\u68b0\u7684\u304a\u3088\u3073\u4ee3\u8b1d\u7684\u56e0\u5b50\u306b\u3088\u308a\u6d3b\u6027\u5316\u3055\u308c\u308b\uff0e\u4e21\u8005\u306e\u56e0\u5b50\u306f\uff0c\u7b4b\u7dda\u7dad\u306b\u4f5c\u7528\u3057\u3066\u76f4\u63a5\u7684\u304b\uff0c\u307e\u305f\u306f\u540c\u5316\u30db\u30eb\u30e2\u30f3\u306e\u5206\u6ccc\u5897\u52a0\u3092\u4ecb\u3057\u3066\u9593\u63a5\u7684\u306b\u30bf\u30f3\u30d1\u30af\u5408\u6210\u3092\u6d3b\u6027\u5316\u3055\u305b\u308b\uff0e\u3053\u308c\u3089\u306e\u56e0\u5b50\u306e\u3046\u3061\uff0c\u6a5f\u68b0\u7684\u304b\u4ee3\u8b1d\u7684\u304b\uff0c\u3044\u305a\u308c\u304c\u91cd\u8981\u306a\u306e\u304b\u3068\u3044\u3046\u7591\u554f\u306b\u7b54\u3048\u3088\u3046\u3068\u8a66\u307f\uff0c\u7570\u306a\u308b\u30bf\u30a4\u30d7\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e\u969b\u306b\uff0c\u7b4b\u6d3b\u52d5\u306e\u30db\u30eb\u30e2\u30f3\u5fdc\u7b54\u3092\u60f9\u8d77\u3057\uff0c\u7b4b\u7d44\u7e54\u306b\u304a\u3051\u308b\u80a5\u5927\u6027\u5909\u5316\u306e\u6a5f\u5e8f\u3092\u5b9a\u7fa9\u3057\u3088\u3046\u3068\u3057\u305f\uff0e<\/p>\n

\u3000\u6210\u9577\u30db\u30eb\u30e2\u30f3\u6fc3\u5ea6\u306e\u5897\u52a0\u304c Ia \u7b4b\u6c42\u5fc3\u6027\u795e\u7d4c\u6d3b\u6027\u306b\u95a2\u9023\u3057\u3066\u3044\u308b\u3068\u306e\u30a8\u30d3\u30c7\u30f3\u30b9\u304c\u3042\u308b (43<\/a>). \u3057\u304b\u3057\uff0c\u591a\u304f\u306e\u8457\u8005\u306f\u540c\u5316\u30db\u30eb\u30e2\u30f3\u6fc3\u5ea6\u5897\u52a0\u304c\u4f5c\u52d5\u7b4b\u3067\u306e\u4ee3\u8b1d\u5909\u5316\u306b\u95a2\u4e0e\u3057\u3066\u3044\u308b\u3068\u8003\u3048\u3066\u3044\u308b (8<\/a>,9<\/a>,44<\/a>,45<\/a>). \u5b9f\u969b\uff0c\u56db\u80a2\u306e\u865a\u8840\u306f\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u304a\u3088\u3073\u597d\u6c17\u6027\u904b\u52d5\u6642\u306e\u30db\u30eb\u30e2\u30f3\u5fdc\u7b54\u3092\u5897\u5f37\u3055\u305b\u308b (10<\/a>,20<\/a>). <\/p>\n

\u3000\u6211\u3005\u306e\u8a66\u9a13 (46<\/a>) \u3067\u306f\uff0c\u5f1b\u7de9\u306a\u3057\u4f4e\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306b\u304a\u3051\u308b\u4f5c\u52d5\u7b4b\u306e\u8840\u6db2\u4f9b\u7d66\u306e\u5236\u9650\u306f\u540c\u5316\u30db\u30eb\u30e2\u30f3\u5206\u6ccc\u3092\u523a\u6fc0\u3059\u308b\u3068\u4eee\u5b9a\u3057\u305f\uff0e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u30d7\u30ed\u30c8\u30b3\u30eb\u306f\u4e0a\u8ff0\u3057\u305f\u8a66\u9a13\u3067\u306e L \u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3068\u540c\u69d8\u3068\u3057\u305f (39<\/a>). <\/p>\n

\u3000\u4f1d\u7d71\u7684\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0 (85% 1RM) \u3068\u5f1b\u7de9\u306a\u3057\u4f4e\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0 (50% 1RM) \u3068\u3067\u306f\u8840\u4e2d\u4e73\u9178\u6fc3\u5ea6\u306e\u5909\u5316\uff0c\u304a\u3088\u3073\u7b4b\u539f\u6027\u30af\u30ec\u30a2\u30c1\u30f3\u30ad\u30ca\u30fc\u30bc\u6d3b\u6027\u306b\u7570\u306a\u308b\u7d50\u679c\u3092\u3082\u305f\u3089\u3059\u3053\u3068\u304c\u5206\u304b\u3063\u305f\uff0e\u4e73\u9178\u306f\u89e3\u7cd6\u7cfb\u306e\u6700\u7d42\u7523\u7269\u3067\u3042\u308b\uff0e\u3086\u3048\u306b\uff0c\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306b\u304a\u3051\u308b\u30a8\u30cd\u30eb\u30ae\u30fc\u4f9b\u7d66\u306f\u4e3b\u306b\u5acc\u6c17\u6027\u7d4c\u8def\u306b\u3088\u308a\uff0c\u8840\u4e2d\u4e73\u9178\u30ec\u30d9\u30eb\u306f\u4f5c\u52d5\u7b4b\u306b\u304a\u3051\u308b\u4ee3\u8b1d\u904e\u7a0b\u306e\u5f37\u5ea6\u3092\u9593\u63a5\u7684\u306b\u793a\u3057\u3066\u3044\u308b\uff0e\u4e88\u60f3\u901a\u308a\uff0c\u4f5c\u52d5\u7b4b\u3078\u306e\u8840\u6db2\u4f9b\u7d66\u306e\u906e\u65ad\u306f\u8840\u4e2d\u4e73\u9178\u6fc3\u5ea6\u306e\u8457\u660e\u306a\u4e0a\u6607\u3092\u4f34\u3063\u305f\uff0e8 \u9031\u9593\u306e\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u671f\u9593\u306e\u958b\u59cb\u6642\uff08\u7b2c 2 \u9031\u4e2d\uff09\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u30bb\u30c3\u30b7\u30e7\u30f3\u5f8c\u306b\uff0c\u4f1d\u7d71\u7684\u306a\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u7fa4\uff08C \u7fa4\uff09\u3067\u306e\u8840\u4e2d\u4e73\u9178\u6fc3\u5ea6\u306f 6.3 mmol\/L \u3067\u3042\u3063\u305f\uff0e\u3057\u304b\u3057\uff0c\u5f1b\u7de9\u306a\u3057\u4f4e\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u7fa4\uff08E \u7fa4\uff09\u3067\u306f 10.8 mmol\/L \u306b\u5897\u52a0\u3057\u3066\u3044\u305f (Table 2<\/strong>). \u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u671f\u9593\u306e\u6700\u5f8c\u306b\u4e21\u7fa4\u9593\u306e\u5dee\u7570\u306f\u6e1b\u5c11\u3057\u305f\uff0e\u3086\u3048\u306b\uff0c\u4e0d\u5b8c\u5168\u306a\u5f1b\u7de9\u3092\u4f34\u3046\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u30bb\u30c3\u30b7\u30e7\u30f3\u5f8c\u306e\u8840\u4e2d\u4e73\u9178\u6fc3\u5ea6\u306f\uff0c\u4ed5\u4e8b\u91cf\u304c\u4f4e\u3044\u306b\u3082\u304b\u304b\u308f\u3089\u305a\uff0c\u4f1d\u7d71\u7684\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u30bb\u30c3\u30b7\u30e7\u30f3\u5f8c\u3088\u308a\u6e1b\u5c11\u3059\u308b\u306e\u3067\u306f\u306a\u304f\u5927\u304d\u304f\u306a\u3063\u305f\uff0e<\/p>\n

\u3000\u8840\u4e2d\u3078\u306e\u7b4b\u539f\u6027\u30af\u30ec\u30a2\u30c1\u30f3\u30ad\u30ca\u30fc\u30bc\u653e\u51fa\u306f\u4f5c\u52d5\u7b4b\u306e\u7d30\u80de\u819c\u306e\u969c\u5bb3\u3092\u9593\u63a5\u7684\u306b\u53cd\u6620\u3057\u3066\u304a\u308a\uff0c\u8ca0\u8377\u91cf\u306b\u4f9d\u5b58\u3059\u308b\u3053\u3068\u304c\u5206\u304b\u3063\u3066\u3044\u308b\uff0e\u4f8b\u3048\u3070\uff0c\u30a8\u30ad\u30bb\u30f3\u30c8\u30ea\u30c3\u30af\u904b\u52d5\u306b\u304a\u3051\u308b CK \u6d3b\u6027\u306e\u4e0a\u6607\u306f\u30b3\u30f3\u30bb\u30f3\u30c8\u30ea\u30c3\u30af\u904b\u52d5\u3088\u308a\u3082\u9065\u304b\u306b\u5927\u304d\u3044 (47,48<\/a>,49<\/a>). \u6211\u3005\u306e\u8a66\u9a13 (46) \u306b\u304a\u3044\u3066\u306f\uff0c\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u671f\u9593\u306e\u7b2c 2 \u9031\u3067\u306e MMCK \u6d3b\u6027\u4e0a\u6607\u306f C \u7fa4\uff08\u4f1d\u7d71\u7684\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\uff09\u3067\u306f E \u7fa4\uff08\u5f1b\u7de9\u306a\u3057\u4f4e\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\uff09\u3088\u308a 73% \u9ad8\u304b\u3063\u305f (258 ± 69 IU\/L vs. 149 ± 36 IU\/L). \u3053\u308c\u306f C \u7fa4\u3067\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u8ca0\u8377\u304c\u3088\u308a\u5927\u304d\u3044\u3053\u3068\u306b\u3088\u308b\u3082\u306e\u3067\u3042\u308b (85% 1RM vs. 50% 1RM). \u304a\u305d\u3089\u304f E \u7fa4\u306e\u88ab\u691c\u8005\u306b\u304a\u3044\u3066\uff0c\u4f5c\u52d5\u7b4b\u3067\u306e\u8840\u6d41\u906e\u65ad\u304c\u7b4b\u7dda\u7dad\u819c\u306e\u969c\u5bb3\u3092\u5897\u5f37\u3057\u306a\u304b\u3063\u305f\u306e\u3060\u308d\u3046\uff0e\u3053\u308c\u306f\u6b21\u306e\u77e5\u898b\u3068\u3082\u4e00\u8cab\u3057\u3066\u3044\u308b\uff0e\u3064\u307e\u308a\uff0c\u4f5c\u52d5\u3057\u3066\u3044\u308b\u56db\u80a2\u306e\u9589\u585e\u306f\u8840\u4e2d CK \u6d3b\u6027\u3092\u4e0a\u6607\u3055\u305b\u306a\u3044\u3068\u3044\u3046\u3053\u3068\u3067\u3042\u308b\uff0e214 mmHg \u306e\u5727\u529b\u3067\u4f5c\u52d5\u7b4b\u306e\u8840\u6d41\u3092\u906e\u65ad\u3057\u305f\u4f4e\u5f37\u5ea6 (20% 1RM) \u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u7fcc\u65e5\u306b\u9589\u585e\u306a\u3057\u3067\u904b\u52d5\u3055\u305b\u305f\u5bfe\u7167\u7fa4\u3068\u540c\u7b49\u306e CK \u30ec\u30d9\u30eb\u3067\u3042\u3063\u305f (20<\/a>). <\/p>\n

\u3000\u6211\u3005\u306e\u8a66\u9a13 (46) \u3067\u7528\u3044\u305f\u4e8c\u7a2e\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u8ca0\u8377\u306b\u304a\u3044\u3066\u4e73\u9178\u3068 MMCK \u6fc3\u5ea6\u5909\u5316\u3092\u6bd4\u8f03\u3059\u308b\u3053\u3068\u3067\uff0c\u4ee5\u4e0b\u306e\u3053\u3068\u304c\u793a\u5506\u3055\u308c\u305f\uff0e\u3064\u307e\u308a\uff0c\u4f1d\u7d71\u7684\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306f\u3088\u308a\u5927\u304d\u306a\u7b4b\u7dda\u7dad\u3078\u306e\u6a5f\u68b0\u7684\u969c\u5bb3\u3092\u3082\u305f\u3089\u3057\uff0c\u8840\u4e2d\u3078\u306e MMCK \u653e\u51fa\u306e\u5897\u52a0\u3092\u3082\u305f\u3089\u3059\uff0e\u540c\u6642\u306b\uff0c\u4e0d\u5b8c\u5168\u306a\u5f1b\u7de9\u3067\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u30bb\u30c3\u30b7\u30e7\u30f3\u5f8c\u306b\uff0c\u5f37\u5316\u3055\u308c\u305f\u89e3\u7cd6\u306f\u8840\u4e2d\u3078\u306e\u4e73\u9178\u306e\u8457\u660e\u306a\u84c4\u7a4d\u3092\u3082\u305f\u3089\u3059\uff0e\u3086\u3048\u306b\uff0c\u4f1d\u7d71\u7684\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306f\u4e3b\u306b\u6a5f\u68b0\u95a2\u9023\u523a\u6fc0\u3092\u751f\u6210\u3057\uff0c\u7b4b\u7dda\u7dad\u306b\u304a\u3051\u308b\u540c\u5316\u30d7\u30ed\u30bb\u30b9\u3092\u60f9\u8d77\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\uff0e\u4e00\u65b9\u3067\u4e0d\u5b8c\u5168\u306a\u5f1b\u7de9\u3067\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u5f8c\u306b\u306f\u4ee3\u8b1d\u6027\u5909\u5316\u304c\u3088\u308a\u5f37\u304f\u9032\u5c55\u3059\u308b\uff0e\u4eee\u306b\u4e0d\u5b8c\u5168\u306a\u5f1b\u7de9\u3067\u306e\u904b\u52d5\u306e\u4e3b\u306a\u6a5f\u80fd\u304c\u4f5c\u52d5\u7b4b\u306e\u8840\u6d41\u906e\u65ad\u3067\u3042\u308b\u3068\u4eee\u5b9a\u3059\u308b\u306a\u3089\uff0c\u7b4b\u80a5\u5927\u53cd\u5fdc\u306e\u6a5f\u5e8f\u3092\u8b70\u8ad6\u3059\u308b\u4e0a\u3067\uff0c\u9589\u585e\u72b6\u614b\u4e0b\u3067\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e\u30c7\u30fc\u30bf\u3092\u8003\u616e\u3057\u306a\u304f\u3066\u306f\u306a\u3089\u306a\u3044\uff0e\u4f8b\u3048\u3070 (21<\/a>,22<\/a>) \u3067\u306f 4 \u9031\u9593\u306e\u5acc\u6c17\u7684\u904b\u52d5\uff08\u9031\u306b 4 \u56de 1 \u56de\u3042\u305f\u308a 45 \u5206\u9593\u30b5\u30a4\u30af\u30ea\u30f3\u30b0 \u8ca0\u8377~20% 1RM\uff09\u3092\u6c17\u5bc6\u5ba4\u5185\u306b\u3066\u884c\u3044\uff0c\u4e0b\u534a\u8eab\u3092 50 mmHg \u52a0\u5727\u3057\u305f\u7d50\u679c\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3057\u305f\u811a\u306e\u65ad\u9762\u7a4d\u304c\u5897\u52a0\u3057\uff0c\u305d\u308c\u306f\u4e3b\u306b I \u578b\u304a\u3088\u3073 IIB \u578b\u306e\u7b4b\u7dda\u7dad\u3067\u3042\u3063\u305f\uff0e\u8457\u8005\u3089\u306f\u7b4b\u80a5\u5927\u3092\u6b21\u306e\u4e8c\u3064\u3060\u3068\u307f\u306a\u3057\u3066\u3044\u308b\uff0e\u3064\u307e\u308a\uff0c\u53ce\u7e2e\u30bf\u30f3\u30d1\u30af\u306e\u5897\u52a0<\/strong>\u3068\uff0c\u30b0\u30ea\u30b3\u30fc\u30b2\u30f3\u304a\u3088\u3073\u8d85\u6c34\u548c\u7269\u306e\u5897\u52a0<\/strong>\u3068\u3067\u3042\u308b\uff0e\u4f3c\u305f\u3088\u3046\u306a\u7d50\u679c\u304c\u30a8\u30ea\u30fc\u30c8\u30e9\u30b0\u30d3\u30fc\u9078\u624b\u3067 8 \u9031\u9593\u306e\u30ab\u30d5\u5727 200 mmHg \u3067\u306e\u865a\u8840\u6027\u4f4e\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\uff08\u9031 2 \u56de, 1 \u56de 4 \u30bb\u30c3\u30c8, 50% 1RM\uff09\u3092\u884c\u3044\uff0c\u89b3\u5bdf\u3055\u308c\u3066\u3044\u308b (50<\/a>). Dynamic Force \u306b\u304a\u3051\u308b\u5897\u52a0\u304a\u3088\u3073 MRI \u3067\u306e\u65ad\u9762\u7a4d\u5897\u52a0\u306f\u305d\u308c\u305e\u308c 14%, 15% \u3067\u3042\u3063\u305f\uff0e\u7279\u7570\u7684\u306a\u529b\u304a\u3088\u3073\u7b4b\u96fb\u56f3\u6d3b\u52d5\u306e\u5897\u52a0\u3092\u6bd4\u8f03\u3059\u308b\u3053\u3068\u3067\uff0c\u8457\u8005\u3089\u306f\u7b4b\u4f53\u7a4d\u306e\u5897\u52a0\u306f\u4e3b\u306b\u53ce\u7e2e\u30bf\u30f3\u30d1\u30af\u306b\u3088\u308b\u3068\u306e\u7d50\u8ad6\u306b\u81f3\u3063\u305f\uff0e<\/p>\n

\u3000GH \u304a\u3088\u3073\u30a4\u30f3\u30b9\u30ea\u30f3\u69d8\u6210\u9577\u56e0\u5b50 (IGF-1) \u306e\u5206\u6ccc\u5897\u52a0\u306f\uff0c\u8840\u6d41\u906e\u65ad\u306b\u5bfe\u6297\u3059\u308b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306b\u3088\u308b\u7b4b\u80a5\u5927\u53cd\u5fdc\u306e\u5468\u8fba\u56e0\u5b50\u3068\u8003\u3048\u3089\u308c\u308b\uff0e\u6211\u3005\u306e\u8a66\u9a13 (46) \u3067\u306f\u4e0d\u5b8c\u5168\u306a\u5f1b\u7de9\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u30bb\u30c3\u30b7\u30e7\u30f3\u5f8c\u306e\u8840\u4e2d GH \u6fc3\u5ea6\u306f\u9ad8\u304b\u3063\u305f\uff0e\u7b4b\u7dda\u7dad\u3078\u306e\u6a5f\u68b0\u7684\u52b9\u679c\u304c\u4f1d\u7d71\u7684\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3088\u308a\u3082\u5c0f\u3055\u304b\u3063\u305f\u306b\u3082\u304b\u304b\u308f\u3089\u305a (Table 2). \u5f1b\u7de9\u306a\u3057\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u304c\uff0c\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u30b5\u30a4\u30af\u30eb\u5168\u4f53\u3092\u901a\u3057\u3066\u9ad8\u3044 GH \u53cd\u5fdc\u3092\u3082\u305f\u3089\u3057\u305f\u3053\u3068\u306f\u91cd\u8981\u3067\u3042\u308b\uff0e\u8840\u4e2d GH \u306e\u6709\u610f\u306a\u5897\u52a0\u304c\u9759\u8108\u9589\u585e\u3092\u4f34\u3046\u5acc\u6c17\u6027\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3067\u8a8d\u3081\u3089\u308c\u305f (10<\/a>,20<\/a>). \u8457\u8005\u3089\u306b\u3088\u308b\u3068\uff0c\u8840\u6d41\u3092\u5236\u9650\u3055\u308c\u3066\u4f5c\u52d5\u3057\u3066\u3044\u308b\u7b4b\u8089\u5185\u306e\u4ee3\u8b1d\u7523\u7269\u304c\u5c40\u6240\u7684\u306b\u84c4\u7a4d\u3057\u305f\u53cd\u5fdc\u306b\u304a\u3051\u308b\u6c42\u5fc3\u6027\u795e\u7d4c III \u304a\u3088\u3073 IV \u306e\u6d3b\u6027\u5316\u306b\u3088\u308b\u3068\u3044\u3046 (metaboreflex mechanism<\/strong>). <\/p>\n

\u3000\u6210\u9577\u30db\u30eb\u30e2\u30f3\u306e\u540c\u5316\u52b9\u679c\u306e\u30e1\u30a4\u30f3\u30b7\u30b9\u30c6\u30e0\u30e1\u30c7\u30a3\u30a8\u30fc\u30bf\u30fc\u306f IGF-1 \u3067\u3042\u308b\uff0e\u6210\u9577\u30db\u30eb\u30e2\u30f3\u306b\u523a\u6fc0\u3055\u308c\u305f\u809d\u7d30\u80de\u306b\u3088\u308a\u5168\u8eab\u6027\u306b\u5206\u6ccc\u3055\u308c\uff0c\u53ce\u7e2e\u30bf\u30f3\u30d1\u30af\u6d3b\u52d5\u5f37\u5ea6\u306b\u3088\u308a\u9aa8\u683c\u7b4b\u7dda\u7dad\u304b\u3089\u30aa\u30fc\u30c8\u30af\u30e9\u30a4\u30f3\u306b\u5206\u6ccc\u3055\u308c\u308b (51<\/a>). \u3086\u3048\u306b\uff0c\u8840\u4e2d IGF-1 \u306e\u5897\u52a0\u304c\u9ad8\u5f37\u5ea6\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u5f8c\u306b\u8a18\u9332\u3055\u308c\u305f (12<\/a>,14<\/a>). \u6211\u3005\u306e\u8a66\u9a13 (46) \u3067\u306f\uff0c\u8840\u4e2d IGF-1 \u30ec\u30d9\u30eb\u306e\u5897\u52a0\u306f\u4e0d\u5b8c\u5168\u306a\u5f1b\u7de9\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u30bb\u30c3\u30b7\u30e7\u30f3\u5f8c\uff08\u7b2c 2 \u9031\u304a\u3088\u3073\u7b2c 7 \u9031\uff09\u306b\u306e\u307f\u8a18\u9332\u3055\u308c\u305f\uff0e\u4f1d\u7d71\u7684\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\uff08\u3088\u308a\u5927\u304d\u306a\u6a5f\u68b0\u7684\u8ca0\u8377\u3092\u7279\u5fb4\u3068\u3059\u308b\uff09\u5f8c\u306b\u306f IGF-1 \u6fc3\u5ea6\u306b\u5909\u5316\u306f\u8a8d\u3081\u3089\u308c\u306a\u304b\u3063\u305f (Table 2<\/strong>). \u4e0d\u5b8c\u5168\u306a\u5f1b\u7de9\u306e\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u5f8c\u306e IGF-1 \u5897\u52a0\u306f GH \u5206\u6ccc\u5897\u52a0\u3092\u80cc\u666f\u3068\u3057\u3066\u8d77\u304d\u305f\u3053\u3068\u306f\u7279\u7b46\u3059\u3079\u304d\u3053\u3068\u3067\u3042\u308b (Table 2<\/strong>). <\/p>\n

\u3000\u8840\u6d41\u5236\u9650\u3092\u4f34\u3046\u4f4e\u5f37\u5ea6\u904b\u52d5\u306f\u8840\u4e2d\u30c6\u30b9\u30c8\u30b9\u30c6\u30ed\u30f3\u5024\u3092\u5897\u52a0\u3055\u305b\u306a\u304b\u3063\u305f (Table 2<\/strong>). \u305d\u308c\u306f\u4ed6\u306e\u8457\u8005\u3089\u306e\u30c7\u30fc\u30bf\u3068\u3082\u4e00\u81f4\u3057\u3066\u3044\u308b (52<\/a>). \u540c\u6642\u306b\uff0c\u5f1b\u7de9\u306a\u3057\u306e\u4f4e\u5f37\u5ea6\u904b\u52d5\u306f\u30b3\u30eb\u30c1\u30be\u30fc\u30eb\u5206\u6ccc\u3092\u5897\u52a0\u3055\u305b\uff0c\u305d\u308c\u306f\u660e\u3089\u304b\u306b\uff0c\u3053\u306e\u7a2e\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e\u9ad8\u3044\u7269\u7406\u7684\u30b3\u30b9\u30c8\u3092\u793a\u5506\u3057\u3066\u3044\u308b (Table 2). <\/p>\n

\u3000\u3086\u3048\u306b\uff0c\u5f1b\u7de9\u306a\u3057\u306e\u4f4e\u5f37\u5ea6 (50% 1RM) \u904b\u52d5\u306f\u9ad8\u30ec\u30d9\u30eb\u306e\u8840\u4e2d GH \u304a\u3088\u3073 IGF-1 \u5206\u6ccc\u3092\u3082\u305f\u3089\u3057\uff0c\u305d\u308c\u306f\u4f1d\u7d71\u7684\u65b9\u6cd5\u306e\u3088\u308a\u5927\u304d\u306a\u5916\u90e8\u8ca0\u8377 (85% 1RM) \u3088\u308a\u3082\u9ad8\u3044\uff0e\u304a\u305d\u3089\u304f\uff0c\u3053\u306e\u73fe\u8c61\u306f\u8840\u6d41\u6e1b\u5c11\u306b\u3088\u308b\u4e0d\u5b8c\u5168\u306a\u5f1b\u7de9\u3067\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306b\u304a\u3051\u308b\u7b4b\u8089\u5185\u3078\u306e\u4ee3\u8b1d\u7269\u306e\u3088\u308a\u9ad8\u3044\u84c4\u7a4d\u306b\u3088\u308b\u3082\u306e\u3067\u3042\u308a\uff0c\u5fc5\u7136\u7684\u306b\uff0c\u3053\u306e\u7a2e\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306f\u7b4b\u8089\u306e\u865a\u8840\u72b6\u614b\u4e0b\u3068\u540c\u7b49\u306b\u306a\u308b\uff0e\u3057\u304b\u3057\uff0c\u7279\u7b46\u3059\u3079\u304d\u3053\u3068\u3060\u304c\uff0c\u540c\u5316\u30db\u30eb\u30e2\u30f3\u5206\u6ccc\u306e\u4e8b\u5f8c\u523a\u6fc0\u52b9\u679c\u306e\u4ee3\u8b1d\u53cd\u5c04\u306e\u6a5f\u5e8f\u306f\u3055\u3089\u306a\u308b\u7814\u7a76\u304c\u5fc5\u8981\u3067\u3042\u308b\uff0e\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306b\u5bfe\u3059\u308b\u30db\u30eb\u30e2\u30f3\u5fdc\u7b54\u306e\u7814\u7a76\u306b\u304a\u3044\u3066\uff0c\u7d50\u679c\u306f\u6df7\u4e71\u3057\u3066\u3044\u308b\uff0eWest \u3089\u306f\u7b4b\u529b\u5897\u52a0\u304a\u3088\u3073\u7b4b\u80a5\u5927\u306b\u5bfe\u3059\u308b\u8840\u4e2d\u5185\u56e0\u6027\u30db\u30eb\u30e2\u30f3\u306e\u30ec\u30d9\u30eb\u5dee\u3092\u7814\u7a76\u3057\u305f (53<\/a>). \u8457\u8005\u3089\u306f\u3053\u3046\u7d50\u8ad6\u3057\u3066\u3044\u308b\uff0c\u3064\u307e\u308a\uff0c\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306b\u3088\u308a\u8d77\u3053\u308b\u6210\u9577\u30db\u30eb\u30e2\u30f3\u3068 IGF-1 \u30ec\u30d9\u30eb\u306e\u5897\u52a0\u306f\u7b4b\u80a5\u5927\u30d7\u30ed\u30bb\u30b9\u306e\u4e3b\u8981\u306a\u523a\u6fc0\u3067\u306f\u306a\u3044\u3068\uff0e\u7b4b\u30bf\u30f3\u30d1\u30af\u5408\u6210\u306e\u8abf\u7bc0\u306f\uff0c\u5f7c\u3089\u306b\u3088\u308c\u3070\uff0c\u4e3b\u306b\u7d30\u80de\u5185\u306e\u6a5f\u68b0\u7684\u30fb\u4ee3\u8b1d\u7684\u523a\u6fc0\u306b\u3088\u308b\u3068\u3044\u3046\uff0e<\/p>\n

Effects of high-intensity strength training and low-intensity strength training without relaxation of muscles on the expression of genes regulating myogenesis. <\/h4>\n

\u3000\u904e\u53bb\u5341\u5e74\u9593\u3067\u5206\u5b50\u751f\u7269\u5b66\u7684\u624b\u6cd5\u306f\uff0c\u591a\u69d8\u306a\u8eab\u4f53\u6d3b\u52d5\u306b\u7b4b\u8089\u304c\u9069\u5fdc\u3059\u308b\u6a5f\u5e8f\u3092\u89e3\u660e\u3057\uff0c\u7570\u306a\u308b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u30d7\u30ed\u30b0\u30e9\u30e0\u306e\u52b9\u7387\u3092\u5b9a\u7fa9\u3059\u308b\u306e\u306b\u5e83\u304f\u7528\u3044\u3089\u308c\u3066\u304d\u305f\uff0e\u7b4b\u7d30\u80de\u3067\u767a\u73fe\u3057\u3066\u3044\u308b\u907a\u4f1d\u5b50\u3092\u89e3\u6790\u3059\u308b\u3053\u3068\u3067\uff0c\u500b\u3005\u306e\u88ab\u9a13\u8005\u306b\u72ec\u7acb\u306b\uff0c\u4e00\u3064\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u30bb\u30c3\u30b7\u30e7\u30f3\u306e\u7d50\u679c\u306b\u57fa\u3065\u3044\u3066\uff0c\u7570\u306a\u308b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u30d7\u30ed\u30c8\u30b3\u30eb\u306e\u52b9\u7387\u3092\u8a55\u4fa1\u3059\u308b\u3053\u3068\u304c\u53ef\u80fd\u3068\u306a\u3063\u305f\uff0e1 \u30bb\u30c3\u30b7\u30e7\u30f3\u306e\u9ad8\u5f37\u5ea6\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u304c\uff0c\u56de\u5fa9\u65e5\u3068\u3088\u308a\u9577\u3044\u671f\u9593\u306b\u7b4b\u5f62\u6210\u8abf\u7bc0\u907a\u4f1d\u5b50\u306e\u767a\u73fe\u3092\u5909\u5316\u3055\u305b\u308b\u3053\u3068\u304c\u660e\u3089\u304b\u306b\u306a\u3063\u305f\uff0e\u4f8b\u3048\u3070 IGF-1, MGF, MyoD, Myogenin, \u305d\u3057\u3066\u30df\u30aa\u30b9\u30bf\u30c1\u30f3 (54<\/a>,55<\/a>). \u8840\u6d41\u5236\u9650\u3092\u4f34\u3046\u4f4e\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0 (20% 1RM) \u304c\u7814\u7a76\u3055\u308c\u305f\u907a\u4f1d\u5b50\u767a\u73fe\u306e\u5909\u5316\u306b\u81f3\u308b\u3053\u3068\u3082\u5206\u304b\u3063\u305f\uff0e\u540c\u3058\u5f37\u5ea6\u3067\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3057\u305f\u5bfe\u7167\u7fa4\u306b\u304a\u3044\u3066\u306f\uff0c\u767a\u73fe\u306e\u5909\u5316\u306f\u898b\u3089\u308c\u306a\u304b\u3063\u305f\u306e\u3067\u3042\u308b\u304c (56<\/a>,57<\/a>). \u3053\u308c\u306f\u6b21\u306e\u4e8b\u5b9f\u306b\u3088\u308b\uff0e\u3064\u307e\u308a\uff0c\u4f1d\u7d71\u7684\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3067\u306f\uff0c\u3088\u308a\u5927\u304d\u306a\u5916\u90e8\u8ca0\u8377 (70-90% 1RM) \u304c\u4e3b\u3068\u3057\u3066\u7528\u3044\u3089\u308c\u3066\u3044\u308b\uff0e\u4e00\u65b9\uff0c\u5f15\u7528\u3057\u305f\u8a66\u9a13\u3067\u306f\uff0c\u5bfe\u7167\u7fa4\u3068\u3057\u3066 20% 1RM \u306e\u8ca0\u8377\u304c\u7528\u3044\u3089\u308c\u3066\u304a\u308a\uff0c\u305d\u306e\u7a0b\u5ea6\u306e\u8ca0\u8377\u3067\u306f\u8eab\u4f53\u6d3b\u52d5\u306e\u6d3b\u767a\u306a\u4eba\u306b\u306f\u7b4b\u5f62\u6210\u8abf\u7bc0\u907a\u4f1d\u5b50\u767a\u73fe\u3092\u5909\u5316\u3055\u305b\u308b\u306b\u306f\u5c0f\u3055\u3059\u304e\u308b\u306e\u304b\u3082\u77e5\u308c\u306a\u3044\uff0e\u4e0a\u8ff0\u3057\u305f\u3088\u3046\u306b\uff0c\u8840\u6d41\u3092\u906e\u65ad\u3057\u305f\u904b\u52d5\u3067\u4f5c\u52d5\u7b4b\u306b\u8457\u660e\u306a\u4ee3\u8b1d\u30b9\u30c8\u30ec\u30b9\u3092\u9054\u6210\u3059\u308b\u306b\u306f\u8ca0\u8377\u306f\u5c11\u306a\u304f\u3068\u3082 30-40% 1RM \u3067\u3042\u308b\u3079\u304d\u3060 (25<\/a>). \u3086\u3048\u306b\uff0c\u6211\u3005\u306f\u7b4b\u5f1b\u7de9\u306a\u3057\u306e\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0 (50% 1RM) \u5f8c\u306e\u7b4b\u5f62\u6210\u8abf\u7bc0\u907a\u4f1d\u5b50\u767a\u73fe\u306e\u5909\u5316\u3068\uff0c\u4f1d\u7d71\u7684\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u5f8c\u306e\u5909\u5316\u3068\u3092\u6bd4\u8f03\u3059\u308b\u3053\u3068\u306b\u3057\u305f\uff0e<\/p>\n

\u3000\u904b\u52d5\u6642\u306e\u7570\u306a\u308b\u7b4b\u7fa4\u9593\u306e\u8ca0\u8377\u306e\u518d\u5206\u914d\u52b9\u679c\u3092\u6392\u9664\u3059\u308b\u305f\u3081\uff0c\u307e\u305f\u7d30\u80de\u5185\u30b7\u30b0\u30ca\u30ea\u30f3\u30b0\u306e\u540c\u5316\u30db\u30eb\u30e2\u30f3\u5206\u6ccc\u5897\u52a0\u306e\u30a4\u30f3\u30d1\u30af\u30c8\u3092\u6392\u9664\u3059\u308b\u305f\u3081\u306b\uff0c\u30cb\u30fc\u30a8\u30af\u30b9\u30c6\u30f3\u30b7\u30e7\u30f3\u304c\u9078\u3070\u308c\u305f\uff0e\u5c0f\u3055\u306a\u7b4b\u4f53\u7a4d\u306e\u95a2\u4e0e\u3059\u308b\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3067\u306f\u540c\u5316\u30db\u30eb\u30e2\u30f3\u5206\u6ccc\u5897\u52a0\u306b\u3064\u306a\u304c\u3089\u306a\u3044 (53<\/a>,58<\/a>) \u3053\u3068\u304c\u77e5\u3089\u308c\u3066\u3044\u308b\uff0e\u4eca\u56de\u306e\u8a66\u9a13\u3067\u306f\uff0c\u4f4e\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0 (50% 1RM) \u306b\u304a\u3044\u3066\uff0c\u6bdb\u7d30\u8840\u7ba1\u5185\u306e\u4e73\u9178\u6fc3\u5ea6\u304c\u308f\u305a\u304b\u306b\u4e0a\u6607\u3057\u305f (3.1 ± 0.5 mmol\/L). \u9ad8\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u30bb\u30c3\u30b7\u30e7\u30f3\u5f8c\u306b\u306f 6.3 ± 0.6 mmol\/L \u306b\u307e\u3067\u4e0a\u6607\u3057\u305f\uff0e\u5f1b\u7de9\u306a\u3057\u306e\u4f4e\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u5f8c\u306b\u306f\u4e73\u9178\u6fc3\u5ea6\u306f\u6700\u9ad8\u5024\u306b\u9054\u3057\u305f (7.4 ± 0.5 mmol\/L). \u4e88\u60f3\u3055\u308c\u305f\u3088\u3046\u306b\uff0c\u540c\u5316\u30db\u30eb\u30e2\u30f3\u306e\u542b\u6709\u91cf\u3067\u3042\u308b\u30c6\u30b9\u30c8\u30b9\u30c6\u30ed\u30f3\u3068 IGF-1 \u306f 8 \u9031\u9593\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u5f8c\u3067\u3055\u3048\u5909\u5316\u3057\u306a\u304b\u3063\u305f\uff0eGH \u306e\u542b\u6709\u91cf\u306f\u9ad8\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u5f8c\u306b\u308f\u305a\u304b\u306b\u5897\u52a0\u3057\u305f\uff0e<\/p>\n

\u3000\u4eca\u65e5\u306e\u7dcf\u8aac\u306b\u3088\u308b\u3068\uff0c\u6210\u4eba\u306b\u304a\u3044\u3066\u306f\uff0cIGF-1 \u86cb\u767d\u306f\u9aa8\u683c\u7b4b\u304b\u3089\u5206\u6ccc\u3055\u308c\uff0c\u7b4b\u80a5\u5927<\/strong>\u3092\u8d77\u3053\u3057\u3046\u308b\uff0e\u3053\u308c\u306f\u4e3b\u306b\u30b5\u30c6\u30e9\u30a4\u30c8\u7d30\u80de\u306e\u5206\u5316<\/strong>\u3068\u65e2\u5b58\u306e\u7b4b\u7dda\u7dad\u3078\u306e\u878d\u5408<\/strong>\u306b\u3088\u308b\u3082\u306e\u3067\u3042\u308b (59<\/a>,60<\/a>). \u3055\u3089\u306b\uff0cIGF-1 \u306b\u3088\u308b\u7b4b\u86cb\u767d\u7570\u5316\u306e\u6291\u5236<\/strong>\u52b9\u679c\u3068\u3057\u3066 Akt-FOXO \u30b7\u30b0\u30ca\u30eb\u7d4c\u8def<\/strong> (61) \u304c\u3042\u308a\uff0cAkt-mTORC1 \u306e\u6d3b\u6027\u5316\u306b\u3088\u308b\u30bf\u30f3\u30d1\u30af\u5408\u6210\u7387\u306e\u5897\u52a0<\/strong>\u304c\u8b70\u8ad6\u3055\u308c\u3066\u3044\u308b (60<\/a>,62<\/a>). \u6211\u3005\u306e\u8a66\u9a13\u3067\u306f\uff0c\u56de\u5fa9\u671f\u306b\u304a\u3051\u308b\u30a4\u30f3\u30b9\u30ea\u30f3\u69d8\u6210\u9577\u56e0\u5b50 (IGF-1Ea) \u7b4b\u30a2\u30a4\u30bd\u30d5\u30a9\u30fc\u30e0\u306e\u767a\u73fe\u306f\u5909\u5316\u3057\u3066\u3044\u306a\u304b\u3063\u305f (Fig. 2<\/strong>). <\/p>\n

\"\"<\/a>
Fig. 2. The expression of mRNA of IGF 1Ea (a) and myostatin (b) normalized to the baseline levels, after a single strength training: traditional high-intensity strength training (75% of 1 RMtr), low-intensity training without relaxation (50% of 1 RM no relax), and traditional low-intensity training (50% of 1 RMtr). 0 h, the time of the termination of a training session. * Significant changes (p ≤ 0.05), compared to the baseline levels; # significant difference (\u0440 \u2264 0.05) from the respective parameter of 75% of 1 RM and 50% of 1 RM<\/figcaption><\/figure>\n

\u3000\u7b4b\u8089\u306e\u6210\u9577\u306e\u6291\u5236\u7684\u306a\u8abf\u7bc0\u56e0\u5b50\u3067\u3042\u308b\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\u907a\u4f1d\u5b50\u306e\u767a\u73fe\u3078\u306e\u5f71\u97ff\u3092\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u30ec\u30b8\u30e1\u30f3\u9593\u3067\u6bd4\u8f03\u3057\u305f\uff0e\u5f1b\u7de9\u306a\u3057\u306e\u904b\u52d5\u5f8c 5 \u6642\u9593\u3067\u30df\u30aa\u30b9\u30bf\u30c1\u30f3 mRNA \u6fc3\u5ea6\u306f 4 \u5206\u306e 1 \u306b\u4f4e\u4e0b\u3057\uff0c\u3055\u3089\u306b\u904b\u52d5\u5f8c 22 \u6642\u9593\u307e\u3067\u305d\u306e\u30ec\u30d9\u30eb\u304c\u6301\u7d9a<\/strong>\u3057\u305f (Fig. 2<\/strong>). \u9ad8\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e\u5f8c\u3067\u306f\uff0c\u30df\u30aa\u30b9\u30bf\u30c1\u30f3 mRNA \u6fc3\u5ea6\u306f\u56de\u5fa9\u671f\u306e 22 \u6642\u9593\u5f8c\u307e\u3067\u6301\u7d9a\u7684\u306b\u4f4e\u4e0b\u3057\u305f<\/strong>\uff08\u30c8\u30fc\u30bf\u30eb\u3067 20 \u5206\u306e 1 \u307e\u3067\uff09\uff0e\u7279\u7b46\u3059\u3079\u304d\u3053\u3068\u3060\u304c\uff0c\u4f4e\u5f37\u5ea6\u306e\u4f1d\u7d71\u7684\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u5f8c\u3067\u306f\uff0c\u3053\u306e\u907a\u4f1d\u5b50\u767a\u73fe\u306b\u306f\u5909\u5316\u304c\u306a\u304b\u3063\u305f\uff0e\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\u907a\u4f1d\u5b50\u767a\u73fe\u306e\u4f4e\u4e0b\u306f Akt-mTORC1 \u7d4c\u8def\u306e\u30b7\u30b0\u30ca\u30eb\u30ad\u30ca\u30fc\u30bc\u6d3b\u6027\u306e\u5897\u52a0\u306b\u95a2\u9023<\/strong>\u3057\u3066\u3044\u308b (63<\/a>) \u4e00\u65b9\u3067\uff0c\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\u767a\u73fe\u4f4e\u4e0b\u306f FOXO \u8ee2\u5199\u56e0\u5b50\u306e\u6d3b\u6027\u3092\u4f4e\u4e0b\u3055\u305b\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a, mRNA \u30ea\u30ac\u30fc\u30bc E3 \u306e\u767a\u73fe\u3092\u523a\u6fc0\u3057\u3066\u30b5\u30c6\u30e9\u30a4\u30c8\u7d30\u80de\u306e\u5206\u5316\u3092\u963b\u5bb3\u3059\u308b (64<\/a>,65<\/a>). <\/p>\n

\u3000\u3086\u3048\u306b\uff0c\u30e2\u30fc\u30c9\u306e\u7570\u306a\u308b\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306f\u7b4b\u5f62\u6210\u8abf\u7bc0\u907a\u4f1d\u5b50\u306e\u767a\u73fe\u304c\u7570\u306a\u308b\u7d50\u679c\u3068\u306a\u308b\uff0e\u9ad8\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306f\u5f1b\u7de9\u306a\u3057\u306e\u4f4e\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3088\u308a\u3082\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\u767a\u73fe\u304c\u5927\u304d\u304f\u4f4e\u4e0b\u3059\u308b\uff0e\u660e\u3089\u304b\u306b\uff0c\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e\u7570\u306a\u308b\u578b\u306e\u52b9\u679c\u3092\u8a73\u7d30\u306b\u7279\u5fb4\u3065\u3051\u308b\u305f\u3081\u306b\uff0c\u7b4b\u539f\u7dda\u7dad\u30bf\u30f3\u30d1\u30af\u5408\u6210\u7387\u306e\u5909\u5316\u3068\uff0c\u30bf\u30f3\u30d1\u30af\u5408\u6210\u7387\u3092\u8abf\u7bc0\u3059\u308b\u30b7\u30b0\u30ca\u30eb\u7d4c\u8def\u306e\u6d3b\u6027\u5316\u3092\u8a55\u4fa1\u3057\u306a\u304f\u3066\u306f\u306a\u3089\u306a\u3044\uff0e\u3053\u308c\u3089\u306e\u8ab2\u984c\u306f\u5c06\u6765\u306e\u7814\u7a76\u304c\u89e3\u6c7a\u3059\u3079\u304d\u3067\u3042\u308b\uff0e<\/p>\n

CONCLUSIONS<\/h3>\n

\u3000\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e\u7570\u306a\u308b\u578b\u306e\u52b9\u7387\u3092\u6bd4\u8f03\u3059\u308b\u3053\u3068\u3067\u6b21\u306e\u3053\u3068\u304c\u793a\u3055\u308c\u305f\uff0e\u3059\u306a\u308f\u3061\uff0c\u4f5c\u52d5\u7b4b\u306e\u5f1b\u7de9\u306a\u3057\u306e\u4f4e\u5f37\u5ea6\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0 (50% 1RM) \u5f8c\u306b\u304a\u3044\u3066\u306f\uff0c\u7b4b\u529b\u306e\u80fd\u529b\u306e\u5897\u52a0\u3068\u4f5c\u52d5\u7b4b\u306e\u30b5\u30a4\u30ba\u306e\u5897\u52a0\u3068\u306f\u4f1d\u7d71\u7684\u306a\u9ad8\u5f37\u5ea6\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0 (80-85% 1RM) \u307b\u3069\u306b\u306f\u5927\u304d\u304f\u306a\u3044\uff0e\u7b4b\u80a5\u5927\u306f\u4f1d\u7d71\u7684\u306a\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3067\u3082\u5f1b\u7de9\u306a\u3057\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3067\u3082\u5f15\u304d\u8d77\u3053\u3055\u308c\u308b\u304c\uff0c\u660e\u3089\u304b\u306b\u7570\u306a\u308b\u7d4c\u8def\u3067\u9054\u6210\u3055\u308c\u308b\uff0e\u4f1d\u7d71\u7684\u306a\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3067\u306f\uff0c\u6a5f\u68b0\u7684\u523a\u6fc0\u306f\u7b4b\u7dda\u7dad\u306b\u540c\u5316\u30d7\u30ed\u30bb\u30b9\u3092\u60f9\u8d77\u3057\uff0c\u4e3b\u306b\u751f\u6210\u3055\u308c\u308b\uff0e\u5f1b\u7de9\u306a\u3057\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3067\u306f\uff0c\u7b4b\u8089\u306b\u304a\u3051\u308b\u5acc\u6c17\u53cd\u5fdc\u306e\u6d3b\u6027\u5316\u304c\u660e\u767d\u306b\u306a\u308c\u3070\u306a\u308b\u307b\u3069\uff0c\u4ee3\u8b1d\u53cd\u5fdc\u306e\u7d50\u679c\u3068\u3057\u3066\u8840\u4e2d GH, IGF-1 \u304a\u3088\u3073\u30b3\u30eb\u30c1\u30be\u30fc\u30eb\u306e\u5206\u6ccc\u5897\u52a0\u304c\u660e\u767d\u306b\u306a\u308b\uff0e\u9ad8\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3068\u7b4b\u5f1b\u7de9\u306a\u3057\u306e\u4f4e\u5f37\u5ea6\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306f\uff0c\u7b4b\u5f62\u6210\u8abf\u7bc0\u907a\u4f1d\u5b50\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\u767a\u73fe\u306e\u52d5\u614b\u306e\u9055\u3044\u306b\u3088\u308a\u7279\u5fb4\u3065\u3051\u3089\u308c\u308b\uff0e\u30c8\u30ea\u30ac\u30fc\u6a5f\u69cb\u306e\u9055\u3044\u306f\uff0c\u4e8c\u7a2e\u985e\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e\u5f71\u97ff\u4e0b\u3067\u306e\u80a5\u5927\u6027\u5909\u5316\u306e\u7279\u5fb4\u306e\u9055\u3044\u3068\u7d44\u307f\u5408\u308f\u305b\u3089\u308c\u308b\uff0e\u53e4\u5178\u7684\u306a\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3067\u306f\uff0c\u65ad\u9762\u7a4d\u306b\u5360\u3081\u308b II \u578b\u7b4b\u7dda\u7dad\u306e\u512a\u5148\u7684\u306a\u5897\u52a0\u3092\u8a8d\u3081\u308b\uff0e\u5f1b\u7de9\u306a\u3057\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3067\u306f\uff0c\u65ad\u9762\u7a4d\u3067\u306f I \u578b\u7b4b\u7dda\u7dad\u306e\u512a\u5148\u7684\u306a\u5897\u52a0\u3092\u8a8d\u3081\u308b\uff0e<\/p>\n

\u3000\u672c\u8a66\u9a13\u306f\u30b9\u30dd\u30fc\u30c4\uff0c\u7279\u306b\u7b4b\u529b\u3068\u6b69\u884c\u7b4b\u306e\u6301\u4e45\u529b\u304c\u9ad8\u5ea6\u306b\u8981\u6c42\u3055\u308c\u308b\u30b9\u30dd\u30fc\u30c4\u306e\u5b9f\u8df5\u306b\u304a\u3044\u3066\u6709\u7528\u3067\u3042\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\uff0e\u3055\u3089\u306b\uff0c\u76f8\u5bfe\u7684\u306b\u4f4e\u8ca0\u8377\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306f\u976d\u5e2f\u3092\u640d\u50b7\u304b\u3089\u4fdd\u8b77\u3059\u308b\uff0e\u3053\u306e\u7279\u5fb4\u306f\u3053\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u30ec\u30b8\u30e1\u30f3\u304c\u30d5\u30a3\u30c3\u30c8\u30cd\u30b9\u53ca\u3073\u30ea\u30cf\u30d3\u30ea\u30c6\u30fc\u30b7\u30e7\u30f3\u533b\u5b66\u306b\u6709\u7528\u3068\u306a\u308b\u3053\u3068\u3092\u53ef\u80fd\u306b\u3057\uff0c\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306f\u5916\u50b7\u5f8c\u306e\u7b4b\u306e\u904b\u52d5\u8010\u5bb9\u80fd\u3092\u30b5\u30dd\u30fc\u30c8\u3059\u308b\u65b9\u6cd5\u3068\u540c\u3058\u304f\u3089\u3044\u5b89\u5168\u3067\u3042\u308b\uff0e<\/p>\n

REFERENCES<\/h3>\n

1. Hurley, B.F., Hanson, E.D., and Sheaff, A.K., Strength training as a countermeasure to aging muscle and chronic disease, Sports Med., 2011, vol. 41, no. 4, p. 289.<\/p>\n

2. Evans, W.J., Meredith, C.N., Cannon, J.G., et al., Metabolic changes following eccentric exercise in trained and untrained men, J. Appl. Physiol., 1986, vol. 61, no. 5, p. 1864.<\/p>\n

3. McCarthy, J.J. and Esser, K.A., Anabolic and catabolic pathways regulating skeletal muscle mass, Curr. Opin. Clin. Nutr. MeTable Care, 2010, vol. 13, no. 3, p. 230.<\/p>\n

4. Suga, T., Okita, K., Takada, S., et al., Effect of multiple set on intramuscular metabolic stress during low intensity resistance exercise with blood flow restriction, Eur. J. Appl. Physiol., 2012, vol. 112, p. 3915.<\/p>\n

5. Takada, S., Okita, K., Suga, T., et al., Low intensity exercise can increase muscle mass and strength proportionally to enhanced metabolic stress under ischemic conditions, J. Appl. Physiol., 2012, vol. 113, no. 2, p. 199.<\/p>\n

6. Ingwall, J.S., Weiner, C.D., Morales, M.F., et al., Specificity of creatine in the control of muscle protein synthe sis, J. Cell Biol., 1974, vol. 62, no. 1, p. 145.<\/p>\n

7. Wallimann, T., Tokarska-Schlattner, M., and Schlattner, U., The creatine kinase system and pleiotropic effects of creatine, Amino Acids, 2011, vol. 40, no. 5, p. 1271.<\/p>\n

8. Lin, H.S., Wang, W., Wang, R.Y., et al., Stimulatory effect of lactate on testosterone production by rat leydig cells, J. Cell Biochem., 2001, vol. 83, p. 147.<\/p>\n

9. Lu, S.S., Lau, C.P., Tung, Y.F., et al., Lactate and the effects of exercise on testosterone secretion: evidence for the involvement of a camp-mediated mechanism, Med. Sci. Sports Exerc., 1997, vol. 29, no. 8, p. 1048.<\/p>\n

10. Viru, M., Jansson, E., Viru, A., et al., Effect of restricted blood flow on exercise-induced hormone changes in healthy men, Eur. J. Appl. Physiol. Occup. Physiol., 1998, vol. 77, no. 6, p. 517.<\/p>\n

11. Ahtiainen, J.P., Pakarinen, A., Alen, M., et al., Muscle hypertrophy, hormonal adaptations and strength development during strength training in strength-trained and untrained men, Eur. J. Appl. Physiol., 2003, vol. 89, no. 6, p. 555.<\/p>\n

12. Kraemer, W.J., Marchitelli, L., Gordon, S.E., et al., Hormonal and growth factor responses to heavy resistance exercise protocols, J. Appl. Physiol., 1990, vol. 69, no. 4, p. 1442.<\/p>\n

13. Kraemer, W.J., Staron, R.S., Hagerman, F.C., et al., The effects of shortterm resistance training on endocrine function in men and women, Eur. J. Appl. Physiol. Occup. Physiol., 1998, vol. 78, no. 1, p. 69.<\/p>\n

14. Rojas, V.S., Knicker, A., Hollmann, W., et al., Effect of resistance exercise on serum levels of growth factors in humans, Horm. MeTable Res., 2010, vol. 42, no. 13, p. 982.<\/p>\n

15. Fry, C.S., Glynn, E.L., Drummond, M.J., et al., Blood flow restriction exercise stimulates mTORC1 signaling and muscle protein synthesis in older men, J. Appl. Physiol., 2010, vol. 108, no. 5, p. 1199.<\/p>\n

16. Fujita, S., Abe, T., Drummond, M.J., et al., Blood flow restriction during low-intensity resistance exercise increases S6K1 phosphorylation and muscle protein synthesis, J. Appl. Physiol., 2007, vol. 103, no. 3, p. 903.<\/p>\n

17. Laurentino, G.C., Ugrinowitsch, C., Roschel, H., et al., Strength training with blood flow restriction diminishes myostatin gene expression, Med. Sci. Sports Exerc., 2012, vol. 44, no. 3, p. 406.<\/p>\n

18. Burgomaster, K.A., Moore, D.R., Schofield, L.M., et al., Resistance training with vascular occlusion: metabolic adaptations in human muscle, Med. Sci. Sports Exerc., 2003, vol. 35, no. 7, p. 1203.<\/p>\n

19. Moore, D.R., Burgomaster, K.A., Schofield, L.M., et al., Neuromuscular adaptations in human muscle following low intensity resistance training with vascular occlusion, Eur. J. Appl. Physiol., 2004, vol. 92, nos. 4\u20135, p. 399.<\/p>\n

20. Takarada, Y., Nakamura, Y., Aruga, S., et al., Rapid increase in plasma growth hormone after low-intensity resistance exercise with vascular occlusion, J. Appl. Physiol., 2000, vol. 88, no. 1, p. 61.<\/p>\n

21. Nygren, A.T., Sundberg, C.J., Goransson, H., et al., Effects of dynamic ischaemic training on human skeletal muscle dimensions, Eur. J. Appl. Physiol., 2000, vol. 82, nos. 1\u20132, p. 137.<\/p>\n

22. Sundberg, C.J., Exercise and training during graded leg ischaemia in healthy man with special reference to effects on skeletal muscle, Acta Physiol. Scand., vol. 615, no. Suppl. 1994, p. 1.<\/p>\n

23. Duchateau, J. and Hainaut, K., Isometric or dynamic training: differential effects on mechanical properties of a human muscle, J. Appl. Physiol., 1984, vol. 56, no. 2, p. 296.<\/p>\n

24. Seluyanov, V.N., Podgotovka beguna na srednie distantsii (Middle Distance Runner Training), Moscow: SporAkademPress, 2001.<\/p>\n

25. Suga, T., Okita, K., Morita, N., et al., Dose effect on intramuscular metabolic stress during low-intensity resistance exercise with blood flow restriction, J. Appl. Physiol., 2010, vol. 108, no. 6, p. 1563.<\/p>\n

26. Nielsen, J.L., Aagaard, P., Bech, R.D., et al., Proliferation of myogenic stem cells in human skeletal muscle in response to low-load resistance training with blood flow restriction, J. Physiol., 2012, vol. 590.<\/p>\n

27. Takada, S., Okita, K., Suga, T., et al., Blood flow restriction exercise in sprinters and endurance runners, Med. Sci. Sports Exerc., 2012, vol. 44, no. 3, p. 413.<\/p>\n

28. Hayot, M., Michaud, A., Koechlin, C., et al., Skeletal muscle microbiopsy: a validation study of a minimally invasive technique, Eur. Respir. J., 2005, vol. 25, no. 3, p. 431.<\/p>\n

29. Bergstrom, J. and Hultman, E., A study of the glycogen metabolism during exercise in man, Scand. J. Clin. Lab. Invest., 1967, vol. 19, no. 3, p. 218.<\/p>\n

30. Pfaffl, M.W., A new mathematical model for relative quantification in real-time RT-PCR, Nucleic Acid Res., 2001, vol. 29, no. 9, p. e45.<\/p>\n

31. Voronov, A.V., Anatomy and biomechanical properties of lower limb muscles and joints, in Fizkul\u2019tura, obrazovanie i nauka (Physical Training, Education, and Science), Moscow, 2003.<\/p>\n

32. Henneman, E., Somjen, G., and Carpenter, D.O., Functional significance of cell size in spinal motoneurons, J. Neurophysiol., 1965, vol. 28, p. 560.<\/p>\n

33. Shenkman, B.S., Litvinova, K.S., Gasnikova, N.M., et al., Creatine as a metabolic controller of skeletal muscles structure and function in strength exercises in humans. The cellular mechanisms, Ross. Fiziol. Zh. im. I.M. Sechenova, 2006, vol. 92, no. 1, p. 100.<\/p>\n

34. Hather, B.M., Tesch, P.A., Buchanan, P., et al., Influence of eccentric actions on skeletal muscle adaptations to resistance training, Acta Physiol. Scand., 1991, vol. 143, no. 2, p. 177.<\/p>\n

35. Houston, M.E., Froese, E.A., Valeriote, S.P., et al., Muscle performance, morphology and metabolic capacity during strength training and detraining: a one leg model, Eur. J. Appl. Physiol. Occup. Physiol., 1983, vol. 51, no. 1, p. 25.<\/p>\n

36. Staron, R.S., Malicky, E.S., Leonardi, M.J., et al., Muscle hypertrophy and fast fiber type conversions in heavy resistance-trained women, Eur. J. Appl. Physiol. Occup. Physiol., 1990, vol. 60, no. 1, p. 71.<\/p>\n

37. Koopman, R., Zorenc, A.H., Gransier, R.J., et al., Increase in S6K1 phosphorylation in human skeletal muscle following resistance exercise occurs mainly in type ii muscle fibers, Am. J. Physiol. Endocrinol. Metab., 2006, vol. 290, no. 6, p. E1245.<\/p>\n

38. Tannerstedt, J., Apro, W., and Blomstrand, E., Maximal lengthening contractions induce different signaling responses in the type i and type ii fibers of human skeletal muscle, J. Appl. Physiol., 2009, vol. 106, no. 4, p. 1412.<\/p>\n

39. Netreba, A.I., Popov, D.V., Lyubaeva, E.V., et al., Physiological effects of using the low intensity strength training without relaxation in single-joint and multi-joint movements, Ross. Fiziol. Zh. im. I.M. Sechenova, 2007, vol. 93, no. 1, p. 27.<\/p>\n

40. Tesch, P., Sjodin, B., and Karlsson, J., Relationship between lactate accumulation, LDH activity, LDH isozyme and fibre type distribution in human skeletal muscle, Acta Physiol. Scand., 1978, vol. 103, no. 1, p. 40.<\/p>\n

41. Humphreys, P.W. and Lind, A.R., The blood flow through active and inactive muscles of the forearm during sustained handgrip contractions, J. Physiol., 1963, vol. 166, p. 120.<\/p>\n

42. Tesch, P. and Karlsson, J., Lactate in fast and slow twitch skeletal muscle fibres of man during isometric contraction, Acta Physiol. Scand., 1977, vol. 99, no. 2, p. 230.<\/p>\n

43. McCall, G.E., Grindeland, R.E., Roy, R.R., et al., Muscle afferent activity modulates bioassayable growth hormone in human plasma, J. Appl. Physiol., 2000, vol. 89, no. 3, p. 1137.<\/p>\n

44. Gordon, S.E., Kraemer, W.J., Vos, N.H., et al., Effect of acid-base balance on the growth hormone response to acute high-intensity cycle exercise, J. Appl. Physiol., 1994, vol. 76, no. 2, p. 821.<\/p>\n

45. Kraemer, W.J., Patton, J.F., Gordon, S.E., et al., Compatibility of high-intensity strength and endurance training on hormonal and skeletal muscle adaptations, J. Appl. Physiol., 1985, vol. 78, no. 3, p. 976.<\/p>\n

46. Popov, D.V., Tsvirkun, D.V., Netreba, A.I., et al., Hormonal adaptation determines the increase in muscle mass and strength during low-intensity strength training without relaxation, Human Physiol., 2006, vol. 32, no. 5, p. 609.<\/p>\n

47. Cerney, F. and Haralambie, G., Exercise-induce loss of muscles enzymes, in Biochemistry of Exercise, Knuttgen, H.G., Ed., Human Kinetics, 1993, p. 441.<\/p>\n

48. Newham, D.J., McPhail, G., Mills, K.R., et al., Ultra structural changes after concentric and eccentric con tractions of human muscle, J. Neurol. Sci., 1983, vol. 61, no. 1, p. 109.<\/p>\n

49. Newham, D.J., Jones, D.A., and Edwards, R.H., Plasma creatine kinase changes after eccentric and concentric contractions, Muscle Nerve, 1986, vol. 9, no. 1, p. 59.<\/p>\n

50. Takarada, Y., Sato, Y., and Ishii, N., Effects of resistance exercise combined with vascular occlusion on muscle function in athletes, Eur. J. Appl. Physiol., 2002, vol. 86, no. 4, p. 308.<\/p>\n

51. Goldspink, G., Mechanical signals, IGFI gene splicing, and muscle adaptation, Physiology (Bethesda), 2005, vol. 20, p. 232.<\/p>\n

52. Reeves, G.V., Kraemer, R.R., Hollander, D.B., et al., Comparison of hormone responses following light resistance exercise with partial vascular occlusion and moderately difficult resistance exercise without occlusion, J. Appl. Physiol., 2006, vol. 101, no. 6, p. 1616.<\/p>\n

53. West, D.W., Burd, N.A., Tang, J.E., et al., Elevations in ostensibly anabolic hormones with resistance exercise enhance neither training-induced muscle hypertrophy nor strength of the elbow flexors, J. Appl. Physiol., 2010, vol. 108, no. 1, p. 60.<\/p>\n

54. McKay, B.R., O\u2019Reilly, C.E., Phillips, S.M., et al., Coexpression of IGF-1 family members with myogenic regulatory factors following acute damaging muscle-lengthening contractions in humans, J. Physiol., 2008, vol. 586.<\/p>\n

55. Yang, Y., Creer, A., Jemiolo, B., et al., Time course of myogenic and metabolic gene expression in response to acute exercise in human skeletal muscle, J. Appl. Physiol., 2005, vol. 98, no. 5, p. 1745.<\/p>\n

56. Drummond, M.J., Fujita, S., Abe, T., et al., Human muscle gene expression following resistance exercise and blood flow restriction, Med. Sci. Sports Exerc., 2008, vol. 40, no. 4, p. 691.<\/p>\n

57. Manini, T.M., Vincent, K.R., Leeuwenburgh, C.L., et al., Myogenic and proteolytic mRNA expression following blood flow restricted exercise, Acta Physiol. (Oxford), 2011, vol. 201, no. 2, p. 255.<\/p>\n

58. Hansen, S., Kvorning, T., Kjaer, M., et al., The effect of short-term strength training on human skeletal muscle: the importance of physiologically elevated hormone levels, Scand. J. Med. Sci. Sports, 2001, vol. 11, no. 6, p. 347.<\/p>\n

59. Jacquemin, V., Furling, D., Bigot, A., et al., IGF-1 induces human myotube hypertrophy by increasing cell recruitment, Exp. Cell Res., 2004, vol. 299, no. 1, p. 148.<\/p>\n

60. Jacquemin, V., ButlerBrowne, G.S., Furling, D., et al., IL-13 mediates the recruitment of reserve cells for fusion during IGF-1-induced hypertrophy of human myotubes, J. Cell Sci., 2007, vol. 120, p. 670.<\/p>\n

61. Sandri, M., Sandri, C., Gilbert, A., et al., Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin1 and cause skeletal muscle atrophy, Cell, 2004, vol. 117, no. 3, p. 399.<\/p>\n

62. Rommel, C., Bodine, S.C., Clarke, B.A., et al., Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K\/Akt\/mTOR AND PI(3)K\/Akt\/GSK3 path ways, Nat. Cell Biol., 2001, vol. 3, no. 11, p. 1009.<\/p>\n

63. Amirouche, A., Durieux, A.C., Banzet, S., et al., Down regulation of Akt\/mammalian target of rapamycin sig naling pathway in response to myostatin overexpression in skeletal muscle, Endocrinology, 2009, vol. 150, no. 1, p. 286.<\/p>\n

64. McFarlane, C., Plummer, E., Thomas, M., et al., Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappab-independent, foxo1-dependent mechanism, J. Cell Physiol, 2006, vol. 209, no. 2, p. 501.<\/p>\n

65. Van Wessel, T., van der Laarse, W.J., et al., The muscle fiber type-fiber size paradox: hypertrophy or oxidative metabolism?, Eur. J. Appl. Physiol., 2010, vol. 110, no. 4, p. 665. <\/p>\n","protected":false},"excerpt":{"rendered":"

\u3000\u4f4e\u5f37\u5ea6\u3068\u9ad8\u5f37\u5ea6\u3068\u306e\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306b\u304a\u3051\u308b\u7b4b\u529b\u3068\u7b4b\u80a5\u5927\u306e\u9069\u5fdc\uff0c\u30b7\u30b9\u30c6\u30de\u30c6\u30a3\u30c3\u30af\u30ec\u30d3\u30e5\u30fc\u3068\u30e1\u30bf\u30a2\u30ca\u30ea\u30b7\u30b9\u306b\u304a\u3044\u3066\u53c2\u8003\u6587\u732e\u306e\u4e00\u3064\u306b\u6319\u3052\u3089\u308c\u3066\u3044\u305f\u8ad6\u6587\u3092\u6284\u8a33\u3059\u308b\uff0e\u30ed\u30b7\u30a2\u304b\u3089\u306e\u7b4b\u751f\u691c\u3092\u542b\u3080\u8cb4\u91cd\u306a\u5831\u544a\u3067\u3042\u308b\uff0e\u3053\u306e\u3088\u3046\u306a\u4fb5\u8972\u7684\u306a\u691c … <\/p>\n

“\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e\u6700\u9069\u5316\uff1a\u5b89\u5168\u306a\u7b4b\u529b\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306b\u304a\u3051\u308b\u65b0\u3057\u3044\u9032\u5c55” \u306e<\/span>\u7d9a\u304d\u3092\u8aad\u3080<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1783,1784,1713,1753,1767,1789,1747,1735,1787,1714,1718,1758,1706,1703,1704,1771,1716,1717,1776,1723,1388,1785,1746,1712,85,1777,1731,1732,1727,1737,1711,404,1742,1719,1761,1773,1721,1765,1707,1762,1781,1786,1709,1748,1720,1490,1710,1739,1728,92,1733,1722,1788,1519,1741,1715,1694,135,1774,1736,1238,1754,1750,1698,1775,1696,1701,1749,1734,1756,1729,91,64,1740,1744,1764,1757,1724,1791,1699,1726,1725,1239,1705,1471,1745,1743,1668,1763,1769,1770,1755,1541,1738,1752,386,1759,1708,1702,1695,78,1768,1779,1760,1772,1782,1697,73,1778,1766,1730,1792,1751,1790,1780,1700],"class_list":["post-2916","post","type-post","status-publish","format-standard","hentry","category-resistance-training","tag-akt-foxo","tag-akt-mtorc1","tag-anabolic-hormones","tag-dimension","tag-dynamic-force","tag-e3","tag-erk1-2","tag-fits","tag-foxo","tag-gene-expression","tag-gh","tag-ia","tag-igf-1","tag-ii","tag-i","tag-metaboreflex-mechanism","tag-mfi","tag-mfii","tag-mgf","tag-micro-biopsy-technique","tag-mri","tag-mrna","tag-mtorc1","tag-muscle-fibers","tag-myod","tag-myogenin","tag-ncl-mhcfab","tag-ncl-mhcs","tag-needle-biopsy-technique","tag-rna","tag-skeletal-muscle","tag-strength-training","tag-1742","tag-1719","tag-1761","tag-1773","tag-1721","tag-1765","tag-1707","tag-1762","tag-1781","tag-1786","tag-1709","tag-1748","tag-1720","tag-1490","tag-1710","tag-1739","tag-1728","tag-92","tag-1733","tag-pcr","tag-1788","tag-1519","tag-1741","tag-1715","tag-1694","tag-135","tag-1774","tag-1736","tag-1238","tag-1754","tag-1750","tag-1698","tag-1775","tag-1696","tag-1701","tag-1749","tag-1734","tag-1756","tag-1729","tag-91","tag-64","tag-1740","tag-1744","tag-1764","tag-1757","tag-1724","tag-1791","tag-1699","tag-1726","tag-1725","tag-1239","tag-1705","tag-1471","tag-1745","tag-1743","tag-1668","tag-1763","tag-iii","tag-iv","tag-1755","tag-1541","tag-dna","tag-1752","tag-386","tag-1759","tag-1708","tag-1702","tag-1695","tag-78","tag-1768","tag-1779","tag-1760","tag-1772","tag-1782","tag-1697","tag-73","tag-1778","tag-1766","tag-1730","tag-1792","tag-1751","tag-1790","tag-1780","tag-1700"],"_links":{"self":[{"href":"https:\/\/www.muscle-hypertrophy.com\/index.php?rest_route=\/wp\/v2\/posts\/2916","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.muscle-hypertrophy.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.muscle-hypertrophy.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.muscle-hypertrophy.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.muscle-hypertrophy.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2916"}],"version-history":[{"count":80,"href":"https:\/\/www.muscle-hypertrophy.com\/index.php?rest_route=\/wp\/v2\/posts\/2916\/revisions"}],"predecessor-version":[{"id":4019,"href":"https:\/\/www.muscle-hypertrophy.com\/index.php?rest_route=\/wp\/v2\/posts\/2916\/revisions\/4019"}],"wp:attachment":[{"href":"https:\/\/www.muscle-hypertrophy.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.muscle-hypertrophy.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.muscle-hypertrophy.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}